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Gram-negative ESKAPE (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp) pathogens are a 
major healthcare concern globally due to their increasing multidrug resistance and ability to 
cause debilitating infections. Phenotypic and genotypic characteristics of multidrug resistant 
Gram-negative ESKAPE pathogens from Komfo Anokye Teaching Hospital in Ghana were 
investigated. Two hundred (200) clinical, non-duplicate Gram-negative bacterial pathogens 
were randomly selected from various human specimens routinely processed by the diagnostic 
microbiological laboratory in the hospital. Multidrug resistant (isolates resistant to at least 
one agent in three or more antibiotic class) isolates selected from each group of Gram-
negative ESKAPE pathogens constituted the final sample. Identification and antibiotic 
susceptibility profiles were carried out using Vitek-2. Identity of isolates for whole genome 
sequencing was further confirmed by MALDI-TOF MS. Four P. aeruginosa and 10 K. 
pneumoniae were subjected to whole genome sequencing based on their extensively drug 
resistant profiles and resistance to third-generation cephalosporins respectively using Illumina 
MiSeq, after genomic DNA extraction using the NucliSens easyMAG®. Antibiotic resistance 
genes and plasmids were identified by mapping the sequence data to an online database using 
ResFinder and plasmidFinder respectively. MLST was also determined from the WGS data. 
The raw read sequences and assembled whole genome contigs have been deposited in 
GenBank under project number PRJNA411997. An average multidrug resistance of 89.5% 
was observed, ranging from 53.8% in Enterobacter spp to 100.0% in Acinetobacter spp and 
P. aeruginosa. Gram-negative ESKAPE bacteria constituted 48.5% (97) of the 200 isolates. P. 
aeruginosa (n=4) belonging to ST234 harboured blaDIM-1, blaIMP-34, blaOXA-10, blaOXA-129, 
blaOXA-50, blaPAO aadA1, aac4 aph(3’)-IIb, fosA, sul1, dfrB5, catB7, arr-2 conferring 
resistance to β-lactams, aminoglycosides, fosfomycin, sulphonamides, trimethoprim 
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phenicols and rifampin respectively. qnrVC was detected in two of the four isolates. Both 
blaDIM-1 and blaIMP-34-like positive contigs showed identical DNA sequences and were linked 
to type 1 integron structures. BlaDIM-1 was 100% identical to the blaDIM-1 prototype gene, 
while blaIMP-34-like had two base pair (bp) differences T190C and C314G respectively 
compared to blaIMP-34, leading to one amino acid substitution in IMP-34-like indicating that, 
the gene may have independently evolved, perhaps due to selection pressure. Blast analysis 
did not reveal identical genetic structures deposited in NCBI, neither among the nucleotide 
collection, completed genomes nor among the completed plasmids. β-lactamases (blaCTX-M-15, 
blaSHV-11, blaTEM-1B) and resistance genes for aminoglycosides (aac(3)-IIa-like,aph(3')-Ia) 
quinolones/fluoroquinolones (oqxA-like,oqxB-like,qnrB10-like,qnrB2) and others including 
fosfomycin (fosA), trimethoprim (dfrA14), and sulphonamide (sul2) were found in the K. 
pneumoniae (n=10). Multiple and diverse mutations of the quinolone resistance-determining 
regions gyrA, gyrB and parC genes were detected in the K. pneumoniae (n=4), which were 
clonally distinct. The diversity of resistance genes expressed by Gram-negative ESKAPE 
pathogens conferring resistance to multiple antibiotics is problematic in a resource-
constrained country like Ghana, necessitating urgent antibiotic stewardship and infection 
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                                                         CHAPTER ONE 
INTRODUCTION 
The escalating rate of bacterial strains acquiring resistance to many clinically relevant antibiotics 
is currently a major global health concern. Antibiotic resistance has an impact on morbidity and 
mortality that is increasingly attributable to infections caused by multi-drug resistant bacteria 
worldwide (Bassetti & Righi, 2015; Brown & Wright, 2016). The mortalities associated with 
drug resistant infections are estimated to increase from the current 700 000 to about 10 million 
annually, and projected to cost the global economy as much as one hundred trillion US dollars by 
the next two decades, if effective measures are not put in place to combat resistance  (O’Neill, 
2014). The emergence and spread of antibiotic resistance is both a community and healthcare-
associated burden, in the developed and developing world, with serious consequences for 
infection prevention and treatment (Carlet & Pittet, 2013; Spellberg & Gilbert, 2014; Ventola, 
2015). Developing countries are considered as key role players, with the burden escalating 
particularly in sub-Saharan African countries such as Ghana, due to sub-optimal enforcement of 
antibiotic control policies and limited logistics for infection surveillance (Holloway et al., 2011; 
Reader, 2015). 
Bacterial pathogens of particular concern and associated with outbreaks of multi-drug resistance 
include the ‘ESKAPE’ pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp), an 
acronym designated by the Infectious Diseases Society of America.  ESKAPE pathogens are the 
leading cause of hospital-acquired infections globally (Navidinia, 2016;Pendleton, Gorman, & 
Gilmore, 2013; Rice, 2010; Santajit & Indrawattana, 2016). Infections caused by multi-drug 
resistant Gram-negative bacteria including those belonging to the ESKAPE group, are of 
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particular significance in both community and hospital settings worldwide, as they are extremely 
challenging to treat, leaving physicians with limited therapeutic options (Cerceo et al., 2016; 
Laxminarayan et al., 2013; Rice, 2010). In Africa, several studies have indicated high antibiotic 
resistance among bacteria including Gram-negative ESKAPE pathogens to mainstay antibiotics 
(Dada-Adegbola & Muili, 2010; Hackman, 2015; Sonda et al., 2016) and resistance is rapidly 
spreading, particularly in sub-Saharan regions where resources are limited for surveillance and 
newly effective antibiotics tend to be unavailable or unaffordable (Baiden et al.,  2010; 
Holloway, Mathai, & Gray, 2011; Jasovský et al., 2016; Laxminarayan et al., 2016). 
Clinical Gram-negative ‘ESKAPE’ (K. pneumoniae, A. baumannii, P. aeruginosa and 
Enterobacter spp) bacteria are associated with high morbidity and mortality and are particularly 
implicated in nosocomial infections (Flynn et al., 2015;Paramythiotou & Routsi, 2016; 
Pendleton et al., 2013). These pathogens are reported to be increasingly resistant to all clinically 
available antibiotic classes including β-lactams (particularly carbapenems and the third- and 
fourth-generation cephalosporins), fluoroquinolones, aminoglycosides and to some extent 
polymixin B (colistin), often used as a  last resort antibiotic (Navidinia, 2016; Lim et al., 2011). 
These bacteria thus feature as critical or high priority pathogens in the World Health 
Organization’s “Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, 
Discovery and Development of New Antibiotics” (WHO, 2017).  
  
The therapeutic options for infections caused by the multi-drug resistant pathogens are very 
limited. Colistin, an old drug with significant toxic side effects and for which there is lack of 
robust data to guide dosage regimens and  duration of therapy, is the last resort antibiotic for 
treatment of infections caused by these resistant organisms (Gallardo-Godoy et al., 2016; 
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Ozsurekci et al., 2016). In addition, some multidrug-resistant Gram-negative isolates including 
P. aeruginosa, A. baumanii, K. pneumoniae and Enterobacter spp have developed resistance to 
colistin (Kaye et al., 2016). A study by Falagas and colleagues evaluating the effectiveness of 
antibiotic treatment commonly administered to patients with infections due to carbapenem-
resistant Enterobacteriaceae reported increasing spread of resistance with mortality rates ranging 
from 26% to 46% (Falagas et al., 2013). A review by Martirosov and Lodise (2016) on emerging 
trends in epidemiology and management of infections due to Enterobacteriaceae highlighted 
increasing resistance among Gram-negative bacteria. They indicated about 64% and 67% deaths 
in patients with extensively drug-resistant Klebsiella spp. and Acinetobacter spp. infections 
despite combination treatment with tigecycline-colistin and carbapenem-colistin respectively 
(Martirosov & Lodise, 2016).  Extensively drug-resistant (XDR) strains of Acinetobacter spp. 
and P. aeruginosa have also been implicated in resistance to colistin (Lim et al., 2011;Bae et al., 
2016; Tseng et al., 2016). 
 
A number of studies in Ghana on antibiotic resistance among Gram-negative bacteria including 
some ESKAPE pathogens have been undertaken in hospitals, but many of the studies were 
centred at Korle-Bu Teaching Hospital in the Greater Accra region of the country (Hackman et 
al., 2014; Obeng-Nkrumah et al., 2013). Apart from the research being in the form of point 
prevalence studies, it has also focused mainly on P. aeruginosa and K. pneumoniae describing 
resistance phenotypes in the main. Two such examples are the ‘phenotypic determination and 
antimicrobial resistance profile of extended spectrum β-lactamases (ESBLs) in E. coli and K. 
pneumoniae’ and ‘antimicrobial sensitivity pattern of urine isolates from large Ghanaian hospital 
by Hackman et al. (2013) and Odonkor et al. (2011) respectively. Literature on the prevalence 
and underlying molecular epidemiology of antibiotic resistance is sparse. To date, there are no 
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published studies on the resistance genotypes of ESKAPE pathogens from Komfo Anokye 
Teaching Hospital, the only referral and tertiary care hospital in the Ashanti region of Ghana. 
This study is thus necessary to expound the underlying molecular mechanisms of resistance of 
Gram-negative ESKAPE pathogens in this setting in order to inform strategies for their 
containment. The results of this study in Ghana are expected to provide information to guide 
policy makers on rational antibiotic use, infection prevention and control measures to combat 
antibiotic resistance in the country and the sub region.  They are additionally expected to yield 

















1.2 LITERATURE REVIEW 
1.2.1 Advent of Antibiotics and Resistance 
The introduction of antibiotics modernized the treatment of bacterial infections. The penicillins 
and sulphonamides were the early antimicrobial drugs to be discovered and developed between 
1920s and 1930s (Aminov, 2017; Marinho et al., 2016). Decades of intense antibiotic drug 
research and technological advances led to the discovery of many new antibiotic classes and 
derivatives of antibiotics among which were the aminoglycosides, tetracyclines, cephalosporins, 
macrolides, glycopeptides, quinolones and carbapenems. These antibiotics became a “wonder 
weapon” for the prevention and treatment of bacterial infections which reduced mortality with a 
marked  shift in patient care (Marinho et al., 2016; Wright, 2014). Among the molecules that 
were successful against a wide-range of bacterial pathogens were the β-lactams, aminoglycosides 
and fluoroquinolones. The emergence and spread of resistance to antibiotics due to abuse or 
misuse has led to a loss in clinical efficacy (Qin, Panunzio, & Biondi, 2014). The high cost of 
discovering novel compounds or chemicals with bacterial  selectivity, the increased regulatory 
requirements for safety and efficacy with low tax incentives for pharmaceutical companies and 
the fact that similar investments made in the development of non-anti-infective drugs could yield 
higher financial returns are major setbacks to the development of new antibiotics (Boucher et al., 
2013; Fernandes, 2015). Thus, evolution of resistance and the waning interest in the development 
of new efficacious antibiotics have resulted in bacterial resistance becoming a global public 
health concern.  
1.2.2 Mechanisms of Action of antibiotics 
The mode of action of antibiotics involves four major mechanisms including interference of 
bacterial cell wall biosynthesis, inhibition of protein synthesis, inhibition of nucleic acid 
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metabolism and repair, and, disruption of membrane structure or permeability of the bacteria 
(Zhou et al., 2015). The enzymes mainly targeted for inhibition in the bacterial cell include 
transpeptidases, transglycosylases, topoisomerases, ribonucleic acid (RNA) polymerase and 
peptidyl transferases. A major component of bacteria cell wall is peptidoglycan layer which 
provides integrity to the cell structure. β-lactam antibiotics such as  penicillins, cephalosporins, 
carbapenems, and monobactams interfere with the cell wall biosynthesis by inhibiting the 
penicillin-binding proteins or transpeptidase enzymes involved in assembly and cross-wall 
linking of the peptidoglycan (Giedraitienė et al., 2011; Sauvage & Terrak, 2016). These agents 
bind to the acyl-D-alanyl-D-alanine amino acid thereby inhibiting the addition of new units to 
the peptidoglycan, thus triggering murein hydrolases or transpeptidases to lyse the cell (Lupoli et 
al., 2011; Münch et al., 2015). The glycopeptides vancomycin and teicoplanin are related to the 
β-lactams that interfere at different stages in cell wall synthesis. These antibiotics bind to 
peptidoglycan units and interfere with the transglycosylase and transpeptidase activity in the 
growing bacteria cell leading to cell inhibition or death (Kahne et al., 2005).   
Protein synthesis is a vital metabolic process necessary for the replication and survival of all 
bacterial cells. Aminoglycosides, tetracyclines, macrolides and chloramphenicol are examples of 
antibiotic classes that inhibit protein synthesis by binding to either 30S or 50S units of the 
intracellular ribosome. Tetracycline and aminocyclitol (aminoglycosides and spectinomycin) 
classes of antibiotics are 30S ribosome inhibitors that prevent the entry of aminoacyl tRNA to 
the ribosome or bind to 16S rRNA component of the 30S ribosome units in  protein synthesis 
(Chellat, Raguž, & Riedl, 2016). Other classes including lincosamides, streptogramins, 
amphenicol and oxazolidinones also inhibit the 50S ribosome. These antibiotics inhibit either 
initiation of protein translations or translocation of peptidyl-tRNAs thus preventing the 
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elongation reaction of the peptide chain by peptidyl-transferase. By mechanisms of action, these 
interfere with the normal cellular metabolism of the bacteria, leading to the inhibition of growth 
or death of the organism (Giedraitienė et al., 2011; Huang, Zhu, & Melançon, 2015). 
Deoxyribonucleic acid (DNA) replication and repair are crucial to any cell survival including 
bacteria. Antibiotics such as the quinolones, fluoroquinolones and sulphonamides inhibit 
enzymes involved in the DNA or RNA synthesis. For instance DNA gyrase (DNA type II 
topoisomerase) and RNA polymerase are inhibited by quinolones and rifampicin respectively, by 
preventing the supercoiling of DNA which interferes with the cellular processes of DNA 
synthesis, thereby compromising bacterial cell replication and survival (Giedraitienė et al., 2011; 
Zhou et al., 2015). Polymixin B or colistin, a cyclic peptide antibiotic disrupts the bacterial cell 
membrane by interacting with phospholipids thereby increasing the permeability of the 
membrane causing the cell to uptake excess water to induce bacteria death (Velkov, Roberts, 
Nation, Thompson, & Li, 2013). 
1.2.3 Causes of bacterial resistance to antibiotics 
Antibiotics have been effective in curing bacterial infections over decades since their 
introduction. However, misuse for both medical and non-medical purposes, such as failure to 
complete drug courses or overuse by infected individuals as well as the extensive usage in 
animals for therapeutic purposes and as growth promoters, have led to resistance in many clinical 
bacteria strains  by selection pressure (Cabello et al., 2013; Caruso, 2016; Kiguba, Karamagi, & 
Bird, 2016). Consequently, common antibiotics that were previously used to treat infections are 
no longer efficacious. The resistance to currently available antibiotics has led to poor treatment 
outcomes of bacterial infections especially those caused by the Gram-negative bacterial 
pathogens, in many parts of the world particularly the developing countries including Ghana 
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(Hackman, Brown, & Twum-Danso, 2014; Kiguba et al., 2016; Opintan et al., 2015). A review 
of the clinical relevance of ESKAPE pathogens by Pendleton and co-workers (2013) indicated 
that resistant Gram-negative ESKAPE bacteria account for about 15.5% of all bacterial 
infections in Africa compared to 5.0% and 7.1% in America and Europe respectively (Pendleton 
et al., 2013). The high prevalence of antibiotic resistance in Africa, is largely due to 
indiscriminate and inappropriate use of antibiotics in healthcare settings and communities 
(Donkor et al., 2012; Kiguba et al., 2016). 
The indiscriminate use of antibiotics to treat any infection, whether severe or minor, and for 
symptoms in many cases that may not be caused by bacteria have contributed immensely to the 
emergence of resistance (Read & Woods, 2014). In healthcare settings, clinicians are often faced 
with a challenge to address an immediate need of patients, especially in critical conditions for 
treatment, over the consideration of concepts of antibiotic resistance. Particularly, in the out-
patient setting, patients’ expectations for antibiotics has been reported as a major  driving factor 
for over-prescription by clinicians (Huttner et al., 2013). Commentary from the 2013 world 
healthcare-associated infections forum and a non-systematic review on antibiotics stewardship in 
the intensive care unit have indicated that, about 30% to 50% of antibiotics prescribed by 
clinicians are inappropriate and 30% to 60% are unnecessarily prescribed in the ICU (Huttner et 
al., 2013; Luyt et al., 2014; Ventola, 2015).  
In many parts of the world, self-medication with antibiotics typically occurs outside the health 
care system with over 50% purchased and used over-the-counter (Ocan et al., 2015). This is 
particularly serious in the developing countries, including sub-Saharan Africa, where 
inadequacies in healthcare systems such as poor enforcement of legislation policy on antibiotics 
restrictions, have resulted in easy availability of antibiotics without prescriptions (Esimone, 
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Nworu, & Udeogaranya, 2007; Michael, Dominey-Howes, & Labbate, 2014; Ocan et al., 2015). 
This has resulted in many cases in the abuse of antibiotics such as incomplete treatment course 
and inadequate dosing (Ocan et al., 2015), which are major driving factors for evolution of 
resistance.  
The frequency of abuse and inappropriate use of antibacterial agents was reported by Vialle-
Valentin et al. (2012) in their study on predictors of antibiotic use in African communities, 
evidence from medicines household survey in five countries including Gambia, Nigeria, Ghana, 
Kenya and Uganda. The study revealed that of the 95% of individuals with acute illness who 
took medicines, 90% sought healthcare outside homes, with 36% prescribed antibiotics. Of the 
36% antibiotic prescriptions, 31.7% were either given antibiotics based on prescriber’s 
experience or discretion guided by clinical presentation or from untrained personnel (Vialle, 
Valentin, Lecates, Zhang, Desta, & Ross, Degnan, 2012). Many healthcare facilities in sub 
Saharan region, have antibiotic regimen of first-line drugs, mostly limited to ampicillin, 
chloramphenicol, erythromycin, gentamicin, penicillin, tetracycline and trimethoprim-
sulfamethoxazole with second-line antibiotics usually consisting of amikacin, amoxicillin-
clavulanic acid, cefuroxime, ciprofloxacin and nalidixic acid in accordance with their clinical 
guidelines (Howard et al., 2015; Mathur, 2016). These treatment protocols are often used 
without adequate microbiological investigations to guide the treatment of infections, usually 
resulting in inappropriate antibiotic choice (Ab-Rahman, Teng, & Sivasampu, 2016; Ocan et al., 
2015) and consequently leading to high selection pressure favouring antibiotic resistance.   
Antibiotics are also widely used in livestock to treat or prevent infections as well as in animal 
feed stock as growth supplements in both developed and developing countries (Gross, 2013; 
Spellberg & Gilbert, 2014; Ventola, 2015). It is estimated that 25-50% of all antibiotics used in 
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the US are for non-curative purposes such as metaphylaxis, prophylaxis and growth promotion in 
livestock (Fair & Tor, 2014). The unrestrained use has exacerbated the spread of resistance as it 
creates a reservoir of bacteria that become resistant, and can be transmitted to humans through 
the food chain (Ventola, 2015). For example, Gram-negative ESKAPE bacterium such as A. 
baumanni has been  implicated in the dissemination of clinically important resistance 
determinants in poultry (Wilharm et al., 2017). Also a  study on antibiotic resistance and 
phylogenetic characterisation of A. baumannii  isolates from commercial raw meat in 
Switzerland reported contamination with A. baumannii in 48% of poultry meat and 25% of raw 
retailed meat overall , thus serving as a reservoir of resistance (Lupo et al., 2014). In China,  E. 
coli clones, harbouring a plasmid mediated mcr-1 colistin resistance gene, were isolated from 
both animals (swine) and humans (Liu et al., 2016). Further, it has also been reported that, about 
90% of antibiotics used in livestock are excreted in urine and faeces, and widely spread into the 
environment through surface runoff and water bodies (Bartlett, Gilbert, & Spellberg, 2013). This 
affects the environmental microbiome (Bartlett et al., 2013) where bacteria are exposed to sub 
inhibitory or sub lethal doses of antibiotics, the susceptible strains are killed, leaving the resistant 
ones to thrive by natural selection (Chee-Sanford et al., 2009). A study in the UK indicated 
substantial levels of resistance genes to clinically relevant antibiotics including tetracyclines, 
sulfonamides and trimethoprim isolated from water bodies that are fed with runoff effluents from 
livestock farms where antibiotics were used (Rowe et al., 2016). The resistance gene (s) is/are 
passed on to the daughter cells by vertical gene transfer or disseminated among different bacteria 
species on mobile genetic elements such as plasmids, transposons or integrons, by horizontal 
gene transfer (Read & Woods, 2014), and ultimately multiply to form a population that becomes 
completely resistant to the agent.  
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Bacterial resistance to multiple antibiotic classes is currently a common phenomenon in sub-
Saharan region including Ghana, in both community and hospital settings mainly due to 
inappropriate use of antibiotics and increasing spread due to lack of strict infection prevention 
and control and hygiene and sanitation measures (Obeng-Nkrumah et al., 2013; Oduro-Mensah 
et al., 2016). Although the growing public health crisis of antibiotic resistance seems 
overwhelming, it is an issue that has long been anticipated and many key elements for its 
effective management have already been identified. However development of a holistic 
approach, by incorporating especially intense research into the underlying molecular 
mechanisms or factors involved in the resistance is crucial.  
1.2.4 Resistance Mechanisms of Gram-negative ESKAPE pathogens  
The Gram-negative bacteria of the ‘ESKAPE’ group have particularly emerged as multidrug-resistant and 
implicated commonly in hospital-associated infections globally (Navidinia, 2016; Santajit & 
Indrawattana, 2016). Similar to other bacteria, these Gram-negative pathogens have evolved with several 
mechanisms of resistance to overcome the effects of antibiotics in their surrounding environment. These 
include the production of hydrolytic enzymes such as ESBLs and carbapenemases to modify the chemical 
composition of the antibiotics (β-lactams), rendering the agents ineffective (Wilson, 2014). β-lactamases 
capable of hydrolysing the penicillins as well as the first-, second- and third generation cephalosporins 
and aztreonam are the extended spectrum β-lactamases (ESBLs) (Maina, Revathi, & Whitelaw, 2017; 
Sutton, 2014). The production of ESBLs and carbapenemase hydrolytic enzymes among the Gram-
negative bacteria has especially become a public health threat, as few antibiotics are effective against 
them. Other mechanisms involve the overexpression of efflux proteins pumps that extrude or regulate the 
concentration of antibiotics such as fluoroquinolones, macrolide-lincosamide-streptogramin (MLS), 
aminoglycosides and tetracyclines from or within the cell and alterations in outer membrane proteins 
(porins) to decreased uptake or cell wall permeability to antibiotics. In multi-drug resistant bacteria, 
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antibiotic resistance genes may be mobilized on plasmids, transposons or integrons. Antibiotic resistance 
gene(s) may be transferred by conjugation, transformation or transduction to another bacterial species 
(Jansen, Barbosa, & Schulenburg, 2013; Karisetty et al., 2013; Seitz & Blokesch, 2013). During 
conjugation, plasmids carrying resistance are transferred to other bacteria by cell-to-cell transfer 
using pili (Ali, 2018; Davies & Davies, 2010).  Bacteria also acquire resistance by transduction 
via mediation of bacteriophages or transformation in which naked DNA is acquired from the 
environment.  The acquisition of resistance via conjugation, transformation and transduction 
together accounts for more mechanisms of resistance than mutations or natural selection (Chee-
Sanford et al., 2009; Davies & Davies, 2010). Bacteria express different mechanisms of 
resistance to antibiotics, however, in Gram-negative bacteria including members of ESKAPE  
pathogens, production of β-lactamases that are hydrolytic enzymes are most widely described 
(Bush, 2013; Soto, 2013; Navidinia, 2016; Santajit & Indrawattana, 2016).  
1.2.4.1 β-Lactamases 
β-lactamases are enzymes produced by bacteria that mediate resistance to β-lactam antibiotics 
such as penicillins, cephalosporins and carbapenems which are among the safest and commonly 
prescribed antibiotics worldwide (Sekyere, Govinden, & Essack, 2016). The production of β-
lactamases is the most common and important mechanism of resistance in Gram-negative 
bacteria. The β-lactamase genes may be encoded chromosomally or by a diversity of mobile 
genetic elements (plasmid-mediated) such as integrons and transposons (Bush, 2010; Poirel, 
Naas, & Nordmann, 2010). The enzymes catalyse the inactivation of the antibiotics by splitting 
the amide bond of the β-lactam’s  ring (acetylation reaction) rendering it ineffective in the 




The β-lactamases are commonly classified by molecular structure (Ambler classification) or 
functional properties (Bush-Jacoby-Medeiros classification) based on the hydrolysis and 
inhibition characteristics of the enzyme (Bush & Jacoby, 2010). Though, the functional 
classification helps to relate the diverse enzymes to their clinical role, it can be more subjective 
compared to the structural classification which is easier and less complicated. Notwithstanding, 
the molecular or: Ambler classification is widely used currently due to an increasing molecular 
analysis of enzymes (Bush & Jacoby, 2010).  The Ambler or structural classification based on 
amino acid sequence and hydrolytic activity is further grouped into four molecular classes A, C 
and D, which are serine β-lactamases and utilise serine for β-lactam hydrolysis whereas class B 
are metallo-β-lactamases which require divalent zinc ions for hydrolytic activity (Jeon et al., 
2015).  
• Class A 
Group A consists of penicillinases, cephalosporinases, extended-spectrum β-lactamases (ESBLs) 
and carbapenemases including Klebsiella pneumoniae carbapenemase  (KPC) which hydrolyses 
penicillins, cephalosporins as well as carbapenems (Jasper et al., 2015; Jeon et al., 2015; Miller 
& Humphries, 2016; Partridge, 2015). Carbapenemases comprise  chromosomal (IMI-1, NmcA, 
SFC-1, SME-1) and plasmid encoded (KPC-2, GES, IMI-2, derivatives) carbapenemase genes 
and are able to hydrolyse all β-lactams including monobactams (aztreonam) but are inhibited or 
partially inhibited by β-lactamase inhibitors such as sulbactam, tazobactam, or clavulanic acid 
but not ethylene diamine tetra acetic acid [EDTA] (Giedraitienė et al., 2011; Rice, 2010).  
ESBLs have emerged as a significant cause of antibiotic resistance in Gram-negative bacteria. 
Apart from resistance to penicillins, cephalosporins and aztreonam, ESBL-producing bacteria are 
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also associated with resistance to other classes of non-β-lactams including aminoglycosides, 
trimethoprim sulfamethoxazole, fluoroquinolones as well as β-lactams/lactamase-inhibitor 
combinations (Thenmozhi et al., 2014). ESBLs consist of three major classes including 
Temoneira (TEM), sulfhydryl variable (SHV) and Cefotaximase-München (CTX-M) types. 
Widely disseminated among Enterobacteriaceae including K. pneumoniae, Enterobacter spp and 
in non-fermenting bacteria such as P. aeruginosa are TEM-1, TEM-2 and SHV-1 type 
derivatives, which confer resistance to penicillins but not broad-spectrum cephalosporins, and 
are composed of single or multiple code gene mutations (Thenmozhi et al., 2014). The high 
mutation dynamism of TEM and SHV encoded genes have resulted in high level of diversity in 
enzyme types thus increasing spread of antibiotic resistance (Džidić, Šušković, & Kos, 2008). 
Among the Gram-negative ESKAPE pathogens, CTX-Ms have been commonly reported (Zhao 
& Hu, 2013). 
A non-systematic review by Storberg (2014) on ESBL-producing Enterobacteriaceae in Africa, 
reported 10% to 40% and 10% to 96% ESBL-producing isolates sampled from hospital and 
community settings respectively. The study further indicated CTX-M-15, TEM-1 and SHV-1 
type derivatives commonly among Gram-negative bacteria including K. pneumoniae, 
Enterobacter spp. and P. aeruginosa of ESKAPE pathogens. Several studies have also been 
conducted in sub Saharan African countries, including the prevalence and multi-drug resistance 
from community-acquired infections in Nigeria (Adenipekun et al., 2016) and extended-
spectrum β-lactamase producing Enterobacteriaceae among clinical isolates in Burkina Faso 
(Ouedraogo et al., 2016). Reports on resistance patterns of ESBL-producing Klebsiella and E. 
coli isolates in tertiary hospitals in Ghana (Feglo & Adu-Sarkodie, 2016; Hackman et al., 2013), 
have all indicated high prevalence of ESBLs, posing challenges to antibiotic therapy. 
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• Class B 
Group B or metallo-β-lactamases (MBLs) exhibit broad spectrum hydrolytic activity with ability 
to virtually hydrolyse all classes of β-lactam antibiotics including expanded-spectrum 
cephalosporins and carbapenems but not aztreonam. The enzymes are however inhibited by 
dipicolinic acid and EDTA but not β-lactamase inhibitors (Mohamed & Al-Ahmady, 2015). The 
MBLs commonly consist of imipenemase metallo-β-lactamases (IMP), German imipenemase 
(GIM), Seoul imipenemase (SIM), Verona integron encoded metallo-β-lactamases (VIM), and 
the New Delhi metallo-β-lactamase-1 (NDM-1) enzymes with encoding genes located on the 
plasmid or transposons and therefore easily disseminated among the bacteria (Dahiya et al., 
2015; Rice, 2010). The IMP-type MBLs have widely been described in Gram-negative ESKAPE 
pathogens, whiles VIM-type enzymes have been commonly detected in P. aeruginosa and A. 
baumannii. The NDM-1-type enzymes have been widely isolated from K. pneumoniae and 
Enterobacter spp. (Kim et al., 2016; Yong et al., 2009).  
A number of studies conducted in Africa have reported on IMP-, VIM-, and NDM-type as  
common metallo-β-lactamases among Enterobacteriaceae including some Gram-negative 








Table 1 showing studies reporting on metallo-β-lactamases among Gram-negative 
ESKAPE bacteria in Africa 
Country of isolation Organism(s)  MBL-type(s) Reference 






Mellouk et al., 2017 
 
Rodriguez-Martinez et al., 
2010 
Ethiopia A.  baumannii NDM-1 Pritsch et al., 2017 
Nigeria K. pneumoniae NDM-1 Ogbolu & Webber, 2014 






Mushi et al., 2014 






Barguigua et al., 2013 












VIM-1                                
 
Govind et al., 2013 
Sekyere, Govinden, & Essack, 
2016 
Peirano et al., 2012 
Kenya K. pneumoniae NDM-1 Poirel et al., 2011 
Tunisia P. aeruginosa VIM-2 Mansour et al., 2009 




Leski et al., 2013 





Fouad et al., 2013 
Zafer at al., 2014 
 
In Ghana, there is no published study on MBL production among Gram-negative ESKAPE 
pathogen, however the first MBL (VIM-2) with TniC-transposons in P. aeruginosa identified in 
Norway, was isolated from a transferred patient after protracted hospitalization in Ghana 
(Samuelsen et al., 2009). The strain is likely to have imported from Ghana, suggesting MBL 






• Class C 
Group C comprises of penicillinases and cephalosporinases such as AmpC β-lactamase which 
exhibit higher hydrolytic activity against early cephalosporins than benzylpenicillin (Jeon et al., 
2015). These enzymes are chromosomally encoded and commonly consist of ACT-1, FOX-1, 
CMY-2, CMY-10, CMY-19, CMY-37, MIR-1, GC1and  DHA that are predominantly expressed 
by P. aeruginosa and Enterobacteriaceae, particularly in  Enterobacter spp (Peymani et al., 
2016). The AmpC β-lactamases are distinct from ESBLs, hydrolyse aztreonam, all penicillins 
and most cephalosporins (cephamycins and oxyimino-β-lactams). The enzymes are commonly 
resistant to  inhibition by EDTA and most β-lactamases inhibitors except avibactam, a current 
non-β-lactam β-lactamase inhibitor (Bush & Jacoby, 2010). The AmpC expression in many 
Gram-negative bacteria including Enterobacter spp. and P. aeruginosa is low, but inducible 
when exposed to certain β-lactams such as ampicillin, amoxicillin, imipenem and clavulanate 
inhibitors (Jacoby, 2009). Carbapenems are mainly stable to AmpC β-lactamases (Thenmozhi et 
al., 2014), however in some bacteria including A. baumanii, one or more components of the 
induction system are lost, and hyper-production of the enzymes with reduced β-lactam 
accumulation, inactivate carbapenems, particularly ertapenem (Bush & Jacoby, 2010). In P. 
aeruginosa hyper-expression of the intrinsically occurring AmpC confers resistance to extended-
spectrum cephalosporins such as ceftazidime (Rodríguez-Martínez, Poirel, & Nordmann, 2009).  
In Ghana, reports on AmpC β-lactamases among Gram-negative ESKAPE bacteria are sparse, 
however high prevalence of AmpC production in P. aeruginosa has been detected in a teaching 





• Class D 
The group D or oxacillinases (OXA-48) type carbapenemases have a higher hydrolysis affinity 
for  cloxacillin or oxacillin than other penicillins (Sekyere, Govinden, & Essack, 2016). The 
enzymes are plasmid encoded consisting of OXA-11 and OXA-15 as significant members, and 
exhibit ESBL activities which are commonly detected in P. aeruginosa (Bakthavatchalam, 
Anandan, & Veeraraghavan, 2016). The enzymes are variably affected by β-lactamase inhibitors, 
but not inhibited by EDTA (Bush & Jacoby, 2010). The Bush-Jacoby scheme classified the OXA 
enzymes as group 2d, which are all resistant to β-lactamase inhibitors except OXA-18 
(Bakthavatchalam, Anandan, & Veeraraghavan, 2016; Džidić et al., 2008; Sgrignani, Grazioso, 
& De Amici, 2016), while OXA-17 confers high resistance to cefotaxime and cefepime 
(Thenmozhi et al., 2014).  OXA carbapenemases tend to have low catalytic activity towards 
penicillins and cephalosporins, but together with porin mutation and other resistance mechanisms 
in A. baumanii can provide resistance to almost all antibiotics including carbapenems 
(Thenmozhi et al., 2014). In Africa, production of oxacillinases (OXA-23) have been commonly 
identified in A. baumanii in studies from Senegal, Libya, South Africa, Tunisia and Nigeria 
(Mathlouthi et al., 2017; Mugnier, Poirel, Naas & Nordmann, 2010; Olaitan et al., 2013). In 
Nigeria, detection of OXA-10 conferring resistance to carbapenems and most broad--spectrum β-
lactam antibiotics in clinical isolates of P. aeruginosa from various clinical specimens has been 
reported (Odumosu, Adeniyi, & Chandra, 2016).  
1.2.4.2 Efflux pumps  
The efflux pumps are transport proteins that control the concentration of antibiotics within the 
bacteria or export the drug molecules from within the cells into the external environment. In 
antibiotic-resistant Gram-negative bacteria, the membrane proteins function as exporters or 
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efflux pumps that expel a broad array of antibiotics from the cell, thus contributing to multiple 
drug resistance. The efflux pumps are a key mechanism employed by Gram-negative bacteria 
against fluoroquinolones, macrolide-lincosamide-streptogramin (MLS), aminoglycosides and 
tetracyclines conferring multiple resistance to various antibiotics across the bacterial species 
(Lau, Hughes, & Poole, 2014; Nikaido & Pagès, 2012). The efflux pump enzymes may be 
chromosomal or plasmid encoded and generally grouped into two classes, the Adenosine 
Triphosphate (ATP) binding cassette (ABC) and secondary multidrug transporters based on the 
source of energy required for the transport. While the ABC-type utilize energy resulting from 
ATP hydrolysis, secondary transporters require membrane energy in the form of the proton 
motive force (Fernández & Hancock, 2012).   
Secondary multidrug transporters are widely described, and subdivided into four super groups, 
including the small multi-drug resistance, the major facilitator, the resistance nodulation-division 
(RND) and multi-drug and toxic compound extrusion family based on primary homology and 
secondary structures (Sun, Deng, & Yan, 2014). The poly-selective efflux pump, belonging to 
the RND super family is mainly responsible for multidrug resistance in Gram-negative bacteria. 
This pump exports wide range of antibiotics and other chemicals commonly used in the practice 
of medicine (Nikaido & Pagès, 2012). The expression of chromosomal encoded AcrAB-TolC 
and MexAB-OprM efflux pumps of RND super family in especially Enterobacter, P. aeruginosa 
and K. pneumoniae confers resistance to fluoroquinolones and also enhances bacterial survival 
against other toxic compounds (Kocsis & Szabó, 2013). mexAB-oprM and mexCD-oprJ encoded 
efflux pumps are widely characterized and mainly associated with resistance to carbapenems, 
fluoroquinolones and aminoglycosides, commonly identified in P. aeruginosa (Vaez et al., 
2014). The expression of efflux pump oqxAB encoded by the oqxA and oqxB genes is commonly 
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identified in ESBL-producing K. pneumoniae as both chromosomal and plasmid borne contribute 
to reduce activity of quinolones and fluoroquinolones (Rodríguez-Martínez et al., 2012). The 
expression of RND-type efflux pumps AdeABC, AdeDE, AdeFGH, and AdeIJK among Gram-
negative members of ESKAPE, like in other Gram-negative bacteria confers  resistance to 
tetracyclines, fluoroquinolones, aminoglycosides, erythromycin and chloramphenicol (Nikaido & 
Pagès, 2012). 
1.2.4.3 Porin Alteration or Reduced Permeability 
The outer membrane of Gram-negative bacteria is an important barrier, protecting the cell 
against damage by toxic compounds. It contains several specific β-barrel protein channels called 
‘porins’ that are regulated to confer resistance to toxic compounds including antibiotics, 
especially the β-lactams. The porins are classified into several groups including, the general 
porins, which are responsible for determining the permeability barrier, the specific porins 
involved in an uptake of specific compounds and the iron-regulated porins for engagement of 
cytoplasmic membrane energization system for the uptake of special iron complexes with 
bacterial siderophores (Fernández & Hancock, 2012). In Gram-negative bacteria, multi-
component pumps combined with a periplasmic membrane fusion (synthesis) protein (MFP) and 
outer membrane protein (OMP) components transfer substrates across the cell envelope. 
Hydrophobic antibiotics including chloramphenicol and aminoglycosides diffuse into the cell 
through the lipid components of the outer membrane while hydrophilic antibiotics such as β-
lactams pass through water-filled channel (selective porins) in the outer membrane proteins. The 
resistance to antibiotics is acquired through the alteration of the barrier by changing the 
hydrophobic properties of the membrane by either reduced permeability or loss of porins (Miller, 
2016). The reduction of OMP channels or loss of porins is as a result of mutations due to the 
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expression of oprD, carO and ompF in P. aeruginosa, Acinetobacter and Enterobacter spp 
respectively conferring resistance to β-lactams such as imipenem and meropenem (Sun et al., 
2014). In K. pneumoniae loss or reduced expression of the major porins, ompK35 and ompK36 
together with other β-lactamases has been reported to confer resistance to fluoroquinolones, 
chloramphenicol and β-lactams including cephalosporins and carbapenems (Doumith et al., 
2009; Sun et al., 2014). 
1.2.5 Clinical importance of Gram-negative ESKAPE pathogens 
1.2.5.1 Klebsiella pneumoniae  
K. pneumoniae is a Gram-negative, non-motile, oxidase negative and encapsulated bacterium 
belonging to the family Enterobacteriaceae. The polysaccharide capsule is important for 
pathogenicity and virulence determination that protects the bacterium from phagocytosis as well 
as the host’s antibodies. The bacterium is a nosocomial pathogen that causes various forms of 
infections such as pneumonia, blood stream infection or sepsis, urinary tract infections (UTIs), 
wound infections and gastro-intestinal infections in humans, with increasing display of antibiotic 
resistance which usually result in prolonged hospitalization and high mortality (Shon, Bajwa, & 
Russo, 2013; Viale et al., 2013). The pathogen is a major cause of community-acquired 
infections such as pneumonia and meningitis in infants, elderly and immuno-compromised 
patients resulting in high mortality (Giovane & Brooks, 2015; Nordmann & Poirel, 2014; Russo 
et al., 2011). It is among the Gram-negative bacteria that are commonly involved in central line-
associated bloodstream infections, catheter-associated urinary tract infections, ventilator-
associated pneumonia and surgical site infections commonly reported in many hospitals in 
developing countries such as India (Mathur et al., 2016) and Egypt (See et al., 2013). The 
therapeutic choice for treatment of their infections include cephalosporins, amino and carboxy- 
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penicillins as well as monobactams or combination therapy with β-lactamases inhibitors such as 
clavulanate or tazobactam depending on the bacterial susceptibility and patient risk profile 
(Breurec et al., 2013; Vaara, 2010). 
 
The mechanism of resistance employed by K. pneumoniae, like other bacteria mainly include 
antibiotic target modification, reduced cell permeability, increased efflux activity and enzymatic 
deactivation (Kumar et al., 2011). However enzymatic deactivation mediated by β-lactamases is 
widely reported. Most significant enzymes include ESBLs and carbapenemases hydrolysing  
penicillins, cephalosporins and carbapenems (King et al., 2017; Thenmozhi et al., 2014). The 
ESBLs are commonly identified as transmissible β-lactamases in the pathogen and inhibited by 
clavulanic acid, tazobactam or sulbactam (Shaikh et al., 2015; Swain & Padhy, 2016). The 
emergence of the New Delhi metallo-β-lactamase-1 'super-enzyme' in K. pneumoniae confers 
resistance to carbapenems and other broad spectrum β-lactam antibiotics, posing a challenge to 
β-lactam chemotherapy (Baraniak et al., 2016). The enzymatic inactivation of DNA gyrase or 
topoisomerase (IV) encoded by gyrA and parC genes in the bacterium combined with the  
expression of efflux pumps confer resistance to fluoroquinolones and quinolones (Guillard et al., 
2015). 
In sub-Saharan regions including Ghana, several studies have indicated high resistance in K. 
pneumoniae to commonly used antibiotics in health care practice. These include inter alia 
Hackman and co-workers in their studies on phenotypic determination and antibiotic resistance 
profile of extended spectrum β-lactamases among some bacterial pathogens, which recorded high 
resistance in K. pneumoniae  to most commonly used antibiotics including penicillins, 
cephalosporins and some non-β-lactam antibiotics in Ghana (Hackman, Brown, & Twum-Danso, 
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2014). The high prevalence of antibiotic resistance was reiterated by other studies including 
Opintan et al. (2015), Feglo and Adu-Sarkodie (2016), indicating widespread antibiotic 
resistance in the bacterium which has consequently become a serious public health concern. 
1.2.5.2 Acinetobacter baumannii 
A. baumanii is non-fermentative Gram-negative coccobacillus that is strictly aerobic, catalase-
positive and oxidase-negative.  It is a short rod non-motile  opportunistic pathogen, mostly 
isolated from intensive care units and surgical wards in hospitals, where widespread use of 
antibiotics has enabled selection for resistance (Behnia et al., 2014; Higgins et al., 2013). They 
are ubiquitous microbes and grow across a range of temperatures, pH and nutrient levels, making 
them highly adaptable for survival in both human and environmental vectors (Al Atrouni et al., 
2016; Vila, Martí, & Sánchez-Céspedes, 2007).  
The bacterium is commonly implicated in various forms of severe hospital-acquired infections 
including bacteraemia, UTIs, post-neurosurgical meningitis, wounds and burn infections and 
most importantly ventilator-associated pneumonia, particularly in immune compromised patients 
in ICUs (Abdallah et al., 2015; Al Mobarak et al., 2014; Chiang et al., 2015). In the last decade 
A. baumanii, combined with P. aeruginosa and K. pneumoniae, have emerged as the most 
significant Gram-negative nosocomial pathogens, with A. baumanii mostly implicated in 
infections and hospital outbreaks (Abdallah et al., 2015; Sengstock et al., 2010). Crude mortality 
rate of 53% associated with ICU infections have been reported from a teaching hospital in 
Turkey in a study to investigate risk factors associated with mortality of MDR A. baumannii 
infections among hospitalized patients (Gulen et al., 2015). Major surgery,  trauma, burns, 
premature birth, prolonged hospitalization in hospital ICUs, mechanical ventilation, indwelling 
foreign devices and previous antimicrobial therapy have all been identified as the predisposing 
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risk factors for the A. baumanii infections (Visca, Seifert, & Towner, 2011). The pathogen’s 
renowned environmental persistence, broad spectrum of antibiotic resistance and ability to 
withstand dry conditions by widening of the periplasmic space and thickening the cell wall, 
provides it with survival advantages over the other Gram-negatives (Otter, Yezli, & French, 
2014; Trivedi et al., 2015; Visca et al., 2011). 
The resistance of A. baumanii to a broad array of antibiotic classes is a challenge to antibiotic 
therapy in clinical practice. The production of β-lactamases (carbapenemases and ESBLs) 
confers resistance to penicillins, cephalosporins and carbapenems. Imipenem metallo-β-
lactamases and oxacillin (OXA) serine β-lactamases were the first to be isolated from A. 
baumannii resistant to carbapenems (Bush et al., 2013; El Salabi, Walsh, & Chouchani, 2013). 
The swift acquisition of resistance genes to different and multiple classes of antibiotics, such as 
the β-lactams, aminoglycosides, quinolones and tetracyclines has led to the exclusion of these 
antibiotics as treatment options for A. baumannii infections (Sharaf & Gerges, 2016). β-
lactam/lactamases inhibitors combination such as ampicillin-sulbactam possess relatively high 
bactericidal action against A. baumanii isolates, and thus 9 out of 10 (90%) patients with severe 
infections is reported to be effectively treated with the combination therapy in certain clinical 
settings (Fishbain & Peleg, 2010; Peleg, Seifert, & Paterson, 2008). Although with significant 
side effects, colistin, may be used as viable option due to its high activity against A. baumanii, 
(Mardani, 2011).  
Other mechanisms such as up-regulation of existing genes of antibiotic-hydrolytic enzymes, 
expression of efflux pumps and reduced outer membrane permeability contribute to multi-drug 
resistance (Mardani, 2011; Miller, 2016). Multi-resistant  A. baumannii strains possess a 
resistance island with genes encoding efflux pumps and conferring resistance to ammonium-
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based disinfectants (Miller et al., 2016). In addition to the resistance island, epidemic strains 
have been shown to possess open reading frames for all known efflux pump families and super 
families acquired from other species (Pendleton et al., 2013). Clinicians and healthcare providers 
are currently faced with a challenge to manage infections caused by multidrug resistant 
Acinetobacter spp in many hospitals worldwide especially the developing countries such as 
Ghana. In a study conducted by Acquah and co-workers on the susceptibility of bacterial 
etiological agents to commonly used antimicrobial agents in children with sepsis from a teaching 
hospital in Ghana, 100% A. baumannii were resistant to ampicillin, tetracycline and 
cotrimoxazole. Multidrug resistant A. baumannii is a public healthcare threat requiring urgent 
interventions for containment of resistance (Acquah et al., 2013). 
1.2.5.3 Pseudomonas aeruginosa 
P. aeruginosa is a Gram-negative, rod-shaped bacterium, classified as a facultative anaerobe that 
grows on a wide range of substrates and can quickly respond to environmental alterations. It is a 
common opportunistic nosocomial pathogen responsible for various infections, exhibits  high 
antimicrobial resistance and is isolated mostly from patients hospitalised longer than one week, 
with UTIs, wound infections, severe burns and from immuno-compromised patients (De Angelis 
et al., 2014; Nanvazadeh et al., 2013; Tumbarello et al., 2013). Apart from the hospital acquired 
infections it can also cause other infections including respiratory tract infection, bacteraemia, 
endocarditis, meningitis, osteomyelitis, enterocolitis, diarrhoea and ecthyma with about 50% of 
the infections particularly associated with pneumonia being fatal (Hirsch & Tam, 2010; Micek et 
al., 2015). Aminoglycoside combination with antipseudomonal β-lactams such as penicillins and 




P. aeruginosa is one of the candidates of ESKAPE pathogens that exhibits high resistance to 
multiple antibiotic classes including fluoroquinolones, carbapenems, aminoglycosides and 
polymyxins with more than 10% of extended drug resistance isolates resistant to carbapenems in 
many European countries under the European Antimicrobial Resistance Surveillance Network 
(Magiorakos et al., 2012). The most common factor involved in the resistance is MexAB-OprM, 
component of efflux overexpression (Labarca et al., 2016; Morales et al., 2012; Vaez et al., 
2014). The lipopolysaccharide which is the major component of the outer membrane of P. 
aeruginosa serves as a barrier that prevents the passage of large hydrophilic molecules. The 
passage of aminoglycosides and colistin is through interaction with the lipopolysaccharide to 
change the permeability of the membrane while β-lactams and quinolones need to diffuse 
through porin channels (Tomás et al., 2010). The reduction in permeability through the loss of 
outer membrane porins (OprD) is associated with resistance to imipenem and reduced 
susceptibility to meropenem (Fowler & Hanson, 2014; Li et al., 2012; Sun et al., 2016). The 
OprD is also co-regulated with an efflux pump system, MexEF-OprN, which results in highly 
impermeable mutants with up-regulated efflux (Poole, 2011). The occurrence of double 
mutations is less frequent but results in significantly higher rates of antibiotic resistance. The 
hyper mutant strains of P. aeruginosa are often implicated in chronic infections as reported in the 
study on in-vivo evolution of resistance of P. aeruginosa strains isolated from patients admitted 
to an intensive care in Barcelona, Spain hospital (Solé et al., 2015). 
 
The acquisition of resistance to multiple antibiotic classes, especially aminoglycosides and 
fluoroquinolones is mediated by transferable aminoglycoside modifying enzymes, rRNA 
methylases and expression of endogenous efflux systems. The genes encoding aminoglycosides 
modifying enzymes (AMEs) are located on integrons with other genes that are responsible for 
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conferring resistance to other classes of antibiotics, a major cause of the dissemination of 
resistance genes within and between bacterial species (Bush et al., 2013; Garneau-Tsodikova & 
Labby, 2016; Ramirez, Nikolaidis, & Tolmasky, 2013). Studies on laboratory-based nationwide 
surveillance of antimicrobial resistance conducted in Ghana, indicated P. aeruginosa as the 
second most prevalent pathogen implicated in various forms of infections, resulting in the use of 
broad array of antibiotics for treatment (Opintan et al., 2015) resulting in high emergence of 
multidrug resistance by selection pressure.  
1.2.5.4 Enterobacter spp. 
Enterobacter spp. are motile aerobic Gram-negative, facultative anaerobic, non-spore forming 
bacilli that form part of normal intestinal flora belonging to the family Enterobacteriaceae 
(Davin-Regli, 2015). It is an opportunistic and ubiquitous bacterium in the environment and can 
survive on skin and dry surfaces as well as replicate in contaminated fluids, and therefore has a 
high propensity to cause nosocomial infections. The high pathogenicity of the bacteria is mainly 
due to the formation of biofilm and secretion of various forms of cytotoxins such as hemolysins, 
pore-forming toxins and enterotoxins. The relevant species include E. cloacae, E. aerogenes, and 
E. agglomerans most commonly isolated from human clinical specimens (Davin-Regli, 2015; 
Mezzatesta, Gona, & Stefani, 2012).  Sydnor and Pearl (2011) in their review on hospital 
epidemiology and infection control in acute care settings reported high incidence of Enterobacter 
spp implicated in hospital-acquired infections in hospitals, particularly in ICUs with the risk of  
spread among patients due to inadequate adherence to infection control measures in some health 
care centres. The bacteria is a common cause of MDR infections in hospitalised patients, 
including cerebral abscess, pneumonia, meningitis, septicaemia, and wound, UTIs, particularly 
catheter-related UTIs and abdominal cavity or intestinal infections with high morbidity and 
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mortality. Enterobacter spp has also been implicated in various community infections and 
display high resistance to broad spectrum of antibiotics (Davin-Regli & Pagès, 2015).  
 
The species has intrinsic resistance to amoxicillin, ampicillin, first-generation cephalosporins, 
and cefoxitin due to low level production of chromosomal AmpC β-lactamases and resistance to 
third generation cephalosporins mostly caused by overexpression. The species displays high 
resistance to broad spectrum-β-lactam antibiotics such as carbapenems through plasmid-encoded 
ESBLs and carbapenemases, including KPC, VIM, MBLS and OXA-types (Castanheira et al., 
2011; Deshpande et al., 2014). Enterobacter spp have EefABC and AcrAB–TolC efflux genes 
that export antibiotics from the cytosol or periplasmic region into extracellular environment, 
which contribute to the resistance against fluoroquinolones and aminoglycosides (Martins et al., 
2010). Besides colistin and tigecycline, only few antibiotics  are effective against these resistant 
strains due to the multi-drug resistant characteristics and hence there are little or no drugs in the 
'pipeline' that are known to be capable of effectively addressing its mounting health crisis 
(Bergen et al., 2015; Yarlagadda et al., 2015). In Ghana, information on Enterobacter spp 
resistance is sparse, however few studies on antibiotic resistance prevalence including that by 
Obeng-Nkrumah et al. (2013) which sought to investigate the monitoring and evaluation of 
antibiotic resistance in a major teaching hospital, and Newman et al. (2011) in their research on 
antimicrobial resistance drugs in Ghana, have indicated high resistance among the species to 
most first line antibiotics used in the country which gives cause for concern.   
1.2.6 Challenges to resistance control strategies 
The development of novel antibiotics over the past decade has slowed down, failing to keep pace 
with the increasing pandemic of multidrug resistant bacteria, thus putting life at risk in treatment 
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of bacterial infections worldwide (Harbarth et al., 2015). The rapid loss of antibiotic efficacy 
together with  increasing multiple drug resistant bacterial infections is worrisome, and demands 
urgent global concerted effort to contain the crisis (Cole, 2014). The situation is particularly 
threatening in the developing countries including Ghana, where resource constraints impede 
surveillance that can yield reliable data for interventions to combat resistance (Baker, 2015). 
Thus, strengthening the research base and making funding available for antibiotic resistance 
studies should be a priority for the problem of resistance to be effectively tackled in the sub 
Saharan African countries. 
Another problem challenging the control of bacterial resistance may be weak health care systems 
and challenges such as inadequate funds, limited infrastructure and logistics, limited diagnostic 
capabilities, lack of qualified medical and laboratory personnel, poor implementation of infection 
control policies and especially lack of surveillance records for continuous update of prevalence 
in many parts of the world (Perez & Villegas, 2015). Although antibiotic resistance is a current 
global public health concern, there is marginal awareness of the magnitude of the problem, 
particularly in middle and low-income countries due to lack of surveillance systems to inform 
strategies and interventions that can detect prevalence, emerging resistance and inform treatment 
guidelines (Perez & Villegas, 2015). These are major setbacks for effective management and 
control of antibiotic resistance particularly in sub Saharan African countries including Ghana 
(Gandra, Merchant, & Laxminarayan, 2016; Ndihokubwayo et al., 2010; WHO, 2014). 
Strengthening surveillance through implementation of infection control and antibiotic 
stewardship programs as well as improvement of laboratory capacity as recommended by the 
World Health Assembly, 2014 resolution 67.25 on Global Action Plan to tackle antibiotic 
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resistance, is crucial to mitigate the alarming rate of bacteria resistance (Shallcross & Davies, 
2014).   
 
The continuous irrational use of antibiotics is one of the major causes of antibiotic resistance, 
which has been a common practice in Ghana. Studies conducted by Donkor and co-workers on 
self-medication practices with antibiotics among tertiary level students in Accra, 2012, reported 
70% (population size of 600) prevalence of self-medication among tertiary students in Accra, the 
capital of Ghana and projected higher percentages across the country especially in the rural 
communities where illiteracy may be comparatively high (Donkor et al., 2012). Selection 
pressure from antibiotic abuse contributes significantly to the emergence of bacterial resistance 
(Michael et al., 2014). To combat the spread of antibiotic resistance, public education on rational 
use of antibiotics and monitoring through the establishment of national surveillance system for 
tracking drug resistance is necessary. Consequently, intensifying research on antibiotic resistance 
in Ghana and the Sub-Saharan regions is paramount if the current burden of resistance among 
bacterial pathogens including the Gram-negative ESKAPE bacteria presently identified as 
problematic resistance pathogens is to be adequately tackled. Therefore a study to determine the 
resistance factors or molecular profile among the clinical isolates in a teaching hospital in Ghana 
is critical to aid in health care policies, antibiotic protocols and prescription regulations. This will 
also provide quality or improve data on the nature and prevalence of the various resistance genes 
or mechanisms involved in antibiotics resistance in Ghana. Such data can become a baseline for 
further research and comparative studies. 
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1.3 AIM OF STUDY 
The aim of this study is to ascertain the phenotypic and genotypic characteristics of multi-drug 
resistant Gram-negative ESKAPE pathogens from Komfo Anokye Teaching Hospital in Kumasi 
in the Ashanti region of Ghana.  
1.3.1 SPECIFIC OBJECTIVES 
 
 To verify the identity and delineate the antibiotic susceptibility profiles of the Gram-
negative ESKAPE pathogens from the bacteriology laboratory at KATH in Ghana over a 
6-month period by using the Vitek-2 automated system. 
 To phenotypically determine the expression of ESBLs, AmpC, inducible AmpC and 
metallo-β-lactamases by the double disc synergy test for ESBLs, the cefoxitin disc 
sensitivity test for AmpC beta-lactamases, the disk antagonism test for inducible AmpC 
β-lactamase production and the imipenem-EDTA combined disk test respectively.  
 To undertake whole genome sequencing of selected isolates with a view to delineating: 
antibiotic resistance genes and their associated mobile genetic elements as well as their  
multi-locus sequence typing (MLST) profiles 
1.4 STUDY DESIGN AND METHODOLOGY 
1.4.1 Study design 
This was an observational, descriptive study where the phenotypic and genotypic characteristics 
of antibiotic resistance was delineated in Gram-negative ESKAPE pathogens collected over a 6-





1.4.2 Ethical Considerations 
Ethical clearance was obtained from  the Joint Committee of Human Research Publications and 
Ethics, School of Medical Sciences, Kwame Nkrumah University of Technology, Research and 
Development Unit of the Hospital Administration (ref: CHRPE/AP/015/15) and the Biomedical 
Research Ethics Committee of University of Kwa-Zulu Natal (ref: BE 494/14). Voluntary, 
informed consent was obtained from all participants in writing or in the form of a thumb print. 
The document was also read, interpreted and further explained in their local dialect to the 
illiterate participants.  Parents or guardians for minors provided consent after explanation of the 
procedure and the purpose of the study. 
1.4.3 Methodology 
 Study setting 
The study was conducted between February and August 2015, in Komfo Anokye Teaching 
Hospital (KATH) in Kumasi, in the Ashanti region of Ghana. The region covers a total land area 
of 24,389 square kilometres representing 10.2% of the total land area of Ghana. The population 
of the region is concentrated in a few districts, with the Kumasi metropolis accounting for nearly 
one-third of the region’s population of 4,780,380 (Owusu et al., 2015). The facility is a 1000-bed 
tertiary care government hospital. The average daily primary care and specialist outpatient 
attendance was 169 and 954 patients respectively, during the period of study. KATH is the only 
regional and referral hospital that takes care of about 80% of both emergencies and regular 
medical cases in the region and also serves as referral hospital for part of Brong Ahafo, Western, 




 Sampling  
 
Two hundred (200) clinical, non-duplicate Gram-negative bacterial pathogens were randomly 
selected from various human specimens routinely processed by the diagnostic microbiological 
laboratory in the hospital from both in-patients and out-patients. Multidrug resistant (isolates 
resistant to at least one agent in three or more antibiotic class) isolates selected from each group 
of Gram-negative ESKAPE pathogens constituted the final sample.  The specimens were from 
urine (94), wound swabs (45), sputum (24), blood (11), ear swabs (6), pus (5) gastric lavage (4), 
tracheal aspirate (4) urethral swabs (2), pleural fluid (2), ascetic fluid (1), nasal swab (1) and 
bronchial lavage (1). Information on diagnosis, sex, age and ward type was obtained from 
patients’ records. The isolates were maintained on nutrient agar slants and subsequently 
transported by Dalsey Hillblom Lynn (DHL) Express Logistic Company ensuring adequate 
health and safety precautions to South Africa for further investigations as described in the 
objectives.   
 Sample Analysis 
Bacterial identification and antibiotic susceptibilities were determined by the Vitek‑2 
(Biomerieux, France) automated system. Identity of isolates selected for whole genome 
sequencing was further confirmed by MALDI-TOF MS. The genomic DNA extraction and 
libraries were generated using the NucliSens easyMAG® (BioMérieux) and Nextera® kit 
(Illumina) respectively, followed by whole genome sequencing on an Illumina MiSeq platform 
for selected P. aeruginosa and K. pneumoniae isolates based on their extensively drug resistant 
profiles and resistance to second- and third-generation cephalosporins respectively.  Antibiotic 
resistance genes and plasmids were identified by mapping the sequence data to an online 
34 
 
database using ResFinder and plasmidFinder respectively. MLST was also determined from the 
WGS data. The raw read sequences and assembled whole genome contigs have been deposited in 
GenBank under project number PRJNA411997 
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The resistance of bacteria to multiple classes of antibiotics is a major global health concern. 
Extended spectrum-β-lactamase-producing Enterobacterales including Klebsiella pneumoniae 
are among the multidrug-resistant Gram-negative bacteria classified as critical on the World 
Health Organization’s list of priority pathogens for the research and development of new 
antibiotics. ESBL encoding plasmids are commonly associated with genes mediating resistance 
to other antibiotic classes including fluoroquinolones and aminoglycosides, facilitating the 
dissemination of multidrug-resistant bacteria in hospital settings. This study delineated the multi-
locus sequence types, antibiotic resistance genes and associated mobile genetic elements in 
multidrug-resistant K. pneumoniae from a teaching hospital in Ghana. Identification and MIC- 
determinations were done using the Vitek‑2 automated system and confirmed by MALDI-TOF 
MS. DNA extraction was carried out using the NucliSens easyMAG® (BioMérieux) kits and the 
DNA was subjected to Illumina WGS. The isolates were characterised by the presence of diverse 
sequence types (STs) include (ST2171, ST1887, ST2816, ST17, ST152, ST397, ST1788, ST798 
and ST101) and multiple genes encoding resistance to β-lactams (blaCTX-M-15, blaSHV-11, blaTEM-1B, 
blaOXA-1), aminoglycosides (aac(3)-IIa, strB, StrA, aadA16), fluoroquinolones/quinolones 
(qnrB49, qnrB10, oqxA, oqxB) and other antibiotic classes.  Resistance genes were associated 
with plasmids, predominantly IncFIB(K) and ColRNAI. We found multiple and diverse 
mutations in quinolone resistance-determining regions of gyrA, gyrB and parC in isolates 
resistant to ciprofloxacin, but no mutation was detected in gyrB among isolates with a 
ciprofloxacin (MIC ≥4mg/mL). None of the isolates susceptible to ciprofloxacin presented 
mutations. The diverse resistance genes identified in multidrug-resistant K. pneumoniae is a 
major threat to the management of infections in Ghana. The molecular characterization of 




Increasing resistance to multiple antibiotic classes among Gram-negative bacteria is a major 
challenge to physicians and health-care providers in the treatment of infections. Gram-negative 
bacteria are commonly associated with hospital-acquired infections such as ventilator associated 
pneumoniae, bloodstream infections, surgical site infections and urinary tract infections (UTI) 
particularly among immune-compromised patients in intensive care units (ICU) (1). 
Enterobacteriaceae including Klebsiella pneumoniae are prominent hospital-acquired pathogens 
and are listed among the six multidrug-resistant ESKAPE (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter spp.) bacteria described by Infectious Disease Society of America 
(2). Third-generation cephalosporin and carbapenem-resistant Enterobacteriaceae have also been 
ranked as critical priority pathogens for the research, discovery and development of new 
antibiotics by the World Health Organization (3, 4).  
The mechanisms of β-lactam antibiotic resistance employed by Gram-negative bacteria including 
K. pneumoniae involve the expression of β-lactamases with/without other non-enzymatic 
resistance mechanisms such as efflux and/or, outer protein membrane or porin reduction 
rendering the agents ineffective (5-7). The resistance may be intrinsically expressed or acquired. 
Ruppé and colleagues (2015) reported high rates of resistance to β-lactam antibiotics, 
particularly second and third generation cephalosporins among Enterobacteriaceae, ranging from 
10% to 70% in a systematic review on mechanism of antibiotic resistance in Gram-negative 
bacilli in the last decade. The swift acquisition of plasmid-borne extended-spectrum β-lactamases 
(ESBLs), especially those belonging to the TEM, SHV and CTX-M β-lactamase families 
produced by Enterobacteriaceae including K. pneumoniae with high preference for oxyimino-
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cephalosporin hydrolysis is increasing globally (8-11). Plasmids of the IncF group represent one 
of the most common plasmid types contributing to the spread of antibiotic resistance genes in 
Enterobacteriaceae with CTX-M-15-positive IncFIIK plasmids commonly characterized in K. 
pneumoniae (12, 13). The spread of these resistant bacteria has compromised the use of β-
lactams, considered as the safest and most easily available antibiotics for treatment of infections 
in many parts of the world, including Ghana.  
Studies conducted in Ghana have reported K. pneumoniae as a major pathogen responsible for 
UTI (14). A laboratory-based nationwide surveillance of antimicrobial resistance in Ghana by 
Opintan and co-workers reported that K. pneumoniae represented 1.06% of all bacterial 
infections and 1.4% of Gram-negative bacilli (15). Agyepong et al (2018) indicated an increased 
K. pneumoniae resistance of 19% (38/200) of Gram-negative bacteria in their study on multidrug 
bacterial infections in a teaching hospital in Ghana. In spite of the threat posed by multidrug 
resistant Gram-negative bacteria in health care settings in Ghana, there is paucity of molecular 
epidemiology studies. This study, which forms part of a broader study on the molecular profile 
of Gram-negative ESKAPE pathogens in a Ghanaian teaching hospital, delineates the resistance 









Materials and Methods 
Ethical Approval and Voluntary Informed Consent 
Ethical clearance was granted by the Joint Committee of Human Research Publications and 
Ethics, School of Medical Sciences, Kwame Nkrumah University of Technology, Research and 
Development Unit of the Hospital Administration (ref: CHRPE/AP/015/15) and the Biomedical 
Research Ethics Committee of University of Kwa-Zulu Natal (ref: BE 494/14). Voluntary, 
informed consent was obtained from all participants and from parents or guardians for minors in 
written form either signed or by a thumb print after explaining the procedure and purpose of the 
study, using an interpreter as appropriate 
Study Setting 
The study was conducted between February and August 2015 in Komfo Anokye Teaching 
Hospital (KATH) in Kumasi, in the Ashanti region of Ghana. The facility is a 1000-bed tertiary 
care government hospital. The average daily primary care and specialist outpatient attendance 
was 169 and 954 patients respectively during the period of study. The population of the region is 
concentrated in a few districts, with the Kumasi metropolis accounting for nearly one-third of the 
region’s population of 4,780,380 (16). KATH is the only regional and referral hospital that takes 
care of about 80% of both emergencies and regular medical cases in the region and serves as 
referral hospital for parts of Brong Ahafo, Western, Eastern and the Northern regions of Ghana. 
Bacterial Selection and Identification 
The K. pneumoniae sample used in this study was a subset of isolates from a larger study of 200 
clinical, non-duplicate Gram-negative bacterial samples (17).  Of the 200 isolates, 38 were K. 
pneumoniae and of these, 10 multi drug resistant isolates resistant to all second- and third-
generation cephalosporins mainly used as last resort antibiotic in Ghana, were selected for 
genotypic characterization by whole genome sequencing. Bacterial identification and antibiotic 
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susceptibilities were determined by the Vitek‑2 (Biomerieux, France) automated system. Identity 
and MICs were further confirmed by using MALDI-TOF MS (Bruker Daltonic Gmbh, Bremen, 
Germany) broth micro-dilution in accordance with European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) guidelines respectively (18).  K. pneumoniae ATCC700603 
was used as the control strain.  
DNA Extraction and Genome Sequencing 
DNA extraction was carried out using the NucliSens easyMAG® (BioMérieux) kits according to 
the manufacturers’ instructions. The genomic DNA libraries were generated using the Nextera® 
kit (Illumina) followed by sequencing on an Illumina MiSeq platform at the Genomics Resource 
Center at the University of Tromso, the  Arctic University of Norway. Raw sequence reads were 
adaptor and quality-trimmed using Trimmomatic (19). After assembly by using SPAdes  3.11.10 
(20)  assembly quality was assessed by QUAST 4.6.0  (21).  The assembled reads were annotated 
using the Bacterial Analysis Pipeline of software revision 4.2 and National Center for 
Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) searches 
(https://www.ncbi.nlm.nih.gov/genome/annotation_prok/). The antibiotic resistance genes and 
plasmids were identified by mapping the sequence data to an online database using ResFinder 
(22) and plasmidFinder (23) respectively. Multi-locus Sequence Typing (MLST) was also 
determined from the assembled genomes (https://github.com/tseemann/mlst).  Comparative 
genomic analysis was further performed using K. pneumoniae ATCC 13883 (PRJNA244567) as 
reference strain to elucidate the chromosomal mutation resulting in quinolone resistance. 
Phylogenetic Analyses  
To investigate the global phylogeny of the K. pneumoniae isolates, genome assembly datasets 
including metadata were downloaded from the Pathosystems Resource Integration Center 
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(PATRIC) database (https://www.patricbrc.org/). Genomes with less than 400 contigs and with 
MLST and isolation country available were selected and run through parsnp (software designed 
for intraspecific or core genome alignment for high quality assemblies) v.1.2 (24) with “–c ”-
flags enabled to include all the selected genomes in the phylogenetic tree, and random reference 
selection among the included samples. FigTree (http://tree.bio.ed.ac.uk/software/figtree/) and R-
ape package (v5.1) were used to visualize and edit the phylogenetic trees. 
Accession numbers: The raw read sequences and the assembled whole genome contigs have 
been deposited in GenBank. The data is available under project number PRJNA411997. 
 
Results  
The clinical data indicated that K. pneumoniae was frequently implicated in UTI. Antibiotic 
susceptibility profiles showed that all the isolates were resistant to cefuroxime, cefotaxime and 
ceftazidime (second- and third-generation cephalosporin) but sensitive to imipenem, ertapenem, 
meropenem, amikacin and colistin. Eight of the ten isolates were additionally resistant to 
gentamicin, nitrofurantoin and sulfamethoxazole-trimethoprim and six were sensitive to 
ciprofloxacin (Table 1). WGS analysis revealed that all the isolates were predominantly 
characterized by the presence of multiple resistance genes encoding for resistance within and 
between antibiotic classes. The isolates carried 3-5 β-lactamase genes, 3-6 aminoglycoside 
resistance genes, 2-5 fluoroquinolone resistance genes in different permutations and 
combinations (Table 2).  blaCTX-M-15, blaSHV-11, and blaTEM-1B), (aac(3)-IIa-like, aph(3')-Ia and 
aac(6')Ib-cr) and (oqxA-like, oqxB-like, qnrB10-like and qnrB2) were the most common β-lactam 
aminoglycoside and fluoroquinolone resistance genes observed respectively. The isolates were 
also characterised with resistance genes for other antibiotic classes including sul2, fosA, dfrA14 and 
catB7-like encoding resistance for sulphonamide, fosfomycin trimethoprim and phenicol 
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respectively with one of the isolates harbouring the mph(A) resistance gene conferring to 
macrolides. MLST analysis identified ST2171, ST1887, ST2816, ST17, ST152, ST397, ST1788, 
ST798 and ST101 K. pneumoniae strains indicating the circulation of multiple K. pneumoniae 
sequence type in a single hospital. IncFIB(K) and ColRNAI were the most prevalent plasmid 
replicon types among K. pneumoniae isolates (Table 2).   
Phylogenetic analyses including the isolate genomes from this study (n=10) and from a global 
strain collection (n=1158, including 20 South African isolates) show that the isolates from our 
study are widely distributed in the global tree (Figure 1). As visualized, the two ST101-isolates 
from Ghana (P26-75 and P26-81) are closely related to each other and belong to the same 
distinct phylogenetic cluster as the South African lineage of ST101. Moreover, isolates P26-71 
(ST397) and P26-66 (ST152) are closely related to the South African ST14 and South African 
ST323 isolates, respectively. As shown, most branches constitute isolates from diverse 
geographic origin. In A, isolate P27-02 clusters with isolates from China, Thailand, Malaysia, 
UK and USA (diverse STs).  The branch B isolates, P27-01 and P26-63 are closely related to 
each other and to ST17-isolates from the USA. In branch C, P26-71 clusters with isolates 
(mainly ST14) from eight countries, including South Africa. In branch D, P26-79 relates to 
isolates from UK and Norway (diverse STs), and in branch E, P26-78 is most closely related to 
isolates of ST493 from the Netherlands and the USA.  In branch F, P26-66 is located together 
with isolates of diverse origin and STs, while isolates from four countries (diverse STs) collocate 
with P26-62 in branch G. The ST101-cluster situates on branch H, which in addition to the 
Ghanaian and South African isolates includes isolates from UK and Pakistan.
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Table 1. Antibiotic susceptibility profiles of the collected multidrug resistant K. pneumoniae (n=10) 
Isolate 
code 
    Susceptibility profile  - MICs (mg/L) 
Date SPM Diagn
osis 
WT AMC TZP CXM FOX CTX CAZ CFP ETP IMP MEM AMK GEN CIP  TET NIT COL SXT 
P27-01 
[20] 
06/06/2015 Urine UTI O&G ≥32 ≥64   ≥64  4 
  













≥64 4  2 
 
- ≤0.25  ≤0.25  ≤2 
 





 13/06/2015 Urine UTI Surg ≥32 16 
  
≥64  16  ≥64 16  16 
  
≤0.5  ≤0.25  ≤0.25 ≤2  
 











02/06/2015 Urine UTI CH 
 
≥32  32 ≥64  ≤4  
 
32 16  2  
 
≤0.5  ≤0.25  ≤0.25  ≤2  
 















≥64 ≤4  
 




≤0.5  ≤0.25  ≤0.25  ≤2  
 























≤0.5  ≤0.25  ≤0.25  ≤2  
 











 01/07/2015 Urine UTI CH 16  ≥64   ≥64  16  ≥64  16  2 
  
≤0.5  ≤0.25  ≤0.25  ≤2  
 
≥16  ≥4  
 







ICU ≥32  32 ≥64  ≤4 ≥64  16 2 ≤.5  ≤.25  ≤.25 ≤2  ≥16  ≤0.25  ≤1  ≤16  ≤0.5  ≥320 
P26-79 
[202] 
11/03/2015 Urine UTI OPD ≥32 128 ≥64 ≤4  ≥64  16  2  ≤0.5 ≤0.25 ≤0.25 ≤2  ≥16  ≤0.25  ≤0.5 32 ≤0.5 ≥320 
P26-81 
[206] 
14/03/2015 Urine UTI Med 16 32  ≥64 16  ≥6 16 2 ≤0.5 ≤0.25 ≤0.2 ≤2 ≥16  ≥4 ≤0.5 ≥512 ≤0.5 ≥320 
Resistant MICs breakpoint (EUCAST, 2017) >8 >16  >8 NA  >2 >4 >4 >1 >8 >8 >16 >4  >0.5 >2 >64 >2 >4 
AMC- Amoxicillin-Clavulanate, TZP- Piperacillin Tazobactam, CXM-Cefuroxime, FOX-Cefoxitin CTX- Cefotaxime , CAZ- Ceftazidime, CFP- Cefepime, 
ETP- Ertapenem, IMP- Imipenem, MRP-Meropenem, AMK- Amikacin, GEN-Gentamicin, CIP-Ciprofloxacin, TET- Tetracycline, NIT- Nitrofurantoin, COL-









Table. 2 Genotypic characterizations of multidrug-resistant K. pneumoniae isolates from WGS Analysis 
Isolate 
code 
MLST Plasmid replicons                                         Genotypic Resistance Mechanisms Chromosomal  mutation  
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tet(D), dfrA14 



















T408A         
D445E 














strB, ,  
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[117] 
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Unless otherwise stated in the footnote, K. pneumoniae ATCC 13883 (PRJNA244567) was used as reference strain in the comparative genomic 

























Figure 1a Klebsiella pneumoniae global phylogeny as revealed by rapid core genome multi-
alignment (https://github.com/marbl/parsnp). Assembly dataset from this study was analyzed 
together with datasets from the PATRIC database (n=1158) and from South Africa (ref. 35). The 
circular tree was mid-rooted and depicted using Figtree 
(http://tree.bio.ed.ac.uk/software/figtree/). Assembly ID for the downloaded samples and isolate 
ID for the samples from Ghana (n=10; orange) and South Africa (n=20; blue) are given and 
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Figure 1b. Phylogenetic tree of K. pneumoniae strains from Ghana, South Africa and a global 
strain collection drawn from the PATRIC database. Subtrees showing the distribution of the 
Ghanaian isolates in eight in distinct phylogenetic branches (A-H) as indicated by the color codes in the 
global tree. The subtrees rooted (includes branch lengths) and scale of 0.005 (for all the trees) using 
(https://cran.r-project.org/web/packages/ape/ape.pdf). For the isolates included in each of these branches, 
assembly ID, isolation country and MLST are shown.   
 
Discussion 
We report on the complexity of multidrug resistance in ESBL-producing K. pneumoniae isolates 
from a referral hospital in Ghana. The isolates were phylogenetically diverse and clustered with 
geographically distant isolates. They were characterised with diverse and multiple permutations 
and combinations of antibiotic resistance genes. A high prevalence of CTX-M-15 β-lactamases 
was observed, which mediated high-level phenotypic resistance to the second- and third-
generation cephalosporins as indicated in the MICs profile (Table 1 and 2). The resistance genes 
were mainly associated with IncFIB(K) plasmids, with ColRNAI also being common among the 
isolates.   
The isolates were resistant to cefuroxime, cefotaxime ceftazidime, amoxicillin-clavulanate, 
piperacillin-tazobactam, gentamicin, nitrofurantoin and trimethoprim-sulfamethoxazole. This  
poses a serious challenge to antibiotic therapy as these agents are commonly used as empirical 
treatment in Ghana (25). The phenotypic profile was corroborated by the whole genome 
sequencing results as evident from Tables 1 and 2. This is comparable to studies from many parts 
of the world, which reported CTX-M class of β-lactamases as a major resistance mechanism 
among Gram-negative bacteria to oxyimino-cephalosporins, particularly cefotaxime (9, 26), with 
CTX-M-15 being the most common allele in Enterobacteriaceae in Africa (27, 28), including 
Gram-negative ESKAPE bacteria and (28-30), particularly in K. pneumoniae (31).  
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Multiple K. pneumoniae STs were identified in lineage with other isolates from a global strain 
collection, albeit different geographical sources and exchange suggest high genetic diversity and 
clonal expansion of this species, as reported in other studies (28, 32). The CTX-M-15-producing K. 
pneumoniae ST type 101 was first reported  in Greece in an ICU infections outbreak caused by 
ertapenem-resistant K. pneumoniae (33) and then in other countries including Spain, Italy, 
France and Tunisia in hospital outbreaks associated with carbapenem resistance (34). In contrast, 
our isolates were sensitive to carbapenems as these agents have been introduced into the 
Ghanaian clinical practice in recent times, are comparatively more expensive than the mainstay 
antibiotics and used as last-resort agents in treating serious infections. Thus, there is relatively 
low selection pressure for the development of carbapenem resistance. Global phylogeny 
investigation indicated that two of the isolates (P26-75 and P26-81) were of the same sequence 
type (ST101) as the main cluster of carbapenemase-producing K. pneumoniae found in Durban, 
South Africa. Although, this lineage of ST101 isolates have been evolved in different local 
environment and resistance pattern including carbapenem resistance differed in that of our 
isolates.  Also the P26-66 and P26-71 isolates were phylogenetically related to the South African 
ST323 isolate and ST14 isolate respectively (35). This could indicate regional transmission 
perhaps due to international travel between the two countries facilitating the dissemination of 
specific K. pneumoniae STs.  
The predominance of CTX-M-15 and different TEM-types found in this study is associated with 
multidrug-resistance in Enterobacteriaceae. The CTX-M-15 and TEM-, SHV- and OXA-types of 
β-lactamases are plasmid encoded with the tendency to disseminate among various species to confer 
resistance to β-lactams and other non-β-lactam antibiotics including quinolones, chloramphenicol, 
tetracyclines and aminoglycosides (29, 36, 37) as reflected in this study.  
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The IncFIB(K) and ColRNAI plasmids was found in all the isolates being associated with CTX-M-
15 and other resistance genes. This finding is consistent with studies that reported the dissemination 
of CTX-M-15 as mainly harboured on IncFII(K) plasmids in ESBL-producing K. pneumoniae 
isolates (38, 39). Reports from others studies have described IncFIB(K) plasmids as dynamic in 
nature, with the capacity for rapid multi-replicon as well as dissemination of antibiotic resistance 
genes among Enterobacteriaceae (40, 41). 
Our study found qnrB10-like, qnrB49 and qnrB66 variants of the qnrB gene in the isolates (P27-
02, P26-66, P26-75 and P26-81) which mediated quinolone resistance, consistent with a study that 
reported this gene as predominantly encoding for fluoroquinolone/quinolone resistance among K. 
pneumoniae in Africa (27). oqxA and oqxB genes were found together in all the isolates,  
suggesting that, the oqxA and oqxB genes cannot be a major mechanism, particularly as they 
were detected in isolates of both susceptible and much higher MICs or perhaps oqxAB in synergy 
with other mechanism increased fluoroquinolone resistance in the isolates (35). However, studies 
conducted in Africa have reported oqxA and oqxB genes encoding oqxAB protein to mediate 
high fluoroquinolones resistance commonly in K. pneumoniae (35, 42). We also identified 
multiple aminoglycoside (aac(6')Ib-cr, StrA, StrB) and quinolone (qnrB, qnrB66) resistance 
genes which have been reported in other studies to mediate resistance to gentamicin and 
ciprofloxacin  (42, 43).  
Analysis of quinolone resistance-determining regions of gyrA, gyrB and parC genes revealed the 
presence of multiple and diverse mutations in gyrA (S83Y, S83F, D87A, T408A, and D445E), 
gyrB (S558A, A692T) and parC (S440N, S673N, S80I, and N304S) in isolates that were clonally 
distinct. Mutations in gyrA, gyrB and parC genes have been reported as a major mechanism of 
fluoroquinolone/quinolone resistance associated with DNA gyrase and topoisomerase IV 
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alterations in Enterobacteriaceae (44, 45), as the plasmid-mediated resistance genes commonly 
mediate low-level fluoroquinolone/quinolone resistance (46, 35). However, mutations in both 
gyrA and parC are often common and associated with high-level quinolone resistance in 
Enterobacteriaceae than alterations in gyrB (44) as evident in this study. ST101 (P26-75, P26-81) 
and ST152 (P26-66) isolates had the same mutation codons 83 and 87 of the gyrA and at 80 in parC 
genes with no mutation in gyrB gene among isolates with a ciprofloxacin MIC of ≥4mg/L. 
Mutations at  83 and 87 in gyrA and 80 in parC  genes are most common mutation points which 
display major alterations among clinical isolates, associated with fluoroquinolone resistance (44, 47, 
48), with codon 83 commonly reported in fluoroquinolone resistant K. pneumoniae (45, 49). The 
combined effect of S83Y/F, D87A and S80I detected in gyrA and parC genes in the isolates, 
P26-66, P26-75 and P26-81 (MIC ≥4mg/L) in our study could be associated with increased-level 
of ciprofloxacin resistance as previously reported (44, 48). The complexity and diversity of 
resistance gene combinations detected among K. pneumoniae strains in this study and their potential 
for dissemination poses a serious threat to the management of infections by this species in Ghana.  
Conclusion 
This study identified genes encoding resistance for β-lactams, fluoroquinolones, 
aminoglycosides and other antibiotics in diverse permutations and combinations among 
multidrug-resistant K. pneumoniae bacteria in Komfo Anokye Teaching Hospital. There is thus 
an urgent need for epidemiological and molecular studies to understand the dynamics of 
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  Susceptibility profile  - MICs (mg/L) 
SPM Diagno
sis 
AMC TZP CXM FOX CTX CAZ CFP ETP IMP MEM AMK GEN CIP  TET NIT COL SXT 
P27-01 
[20] 
urine UTI ≥32 ≥64   ≥64  4 ≥64 16  8 ≤0.5 ≤0.25  ≤0.25  ≤2  ≥16  ≤0.2 1  64 ≤0.5 ≥320 
P27-02 
[46] 
urine UTI ≥32 16 ≥64 ≤4 ≥64 4  2 - ≤0.25  ≤0.25  ≤2 ≥16  2 1  64 ≤0.5 ≥320  
P26-62 
[70] 
urine UTI ≥32 16 ≥64  16  ≥64 16  16 ≤0.5  ≤0.25  ≤0.25 ≤2  ≥16  ≤0.25  2 64 ≤0.5  ≥320  
P26-63 
[76] 
urine UTI ≥32  32 ≥64  ≤4  
 
32 16  2  
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urine UTI 16  ≥64   ≥64  16  ≥64  16  2 
  
≤0.5  ≤0.25  ≤0.25  ≤2  
 
≥16  ≥4  
 





≥32  32 ≥64  ≤4 ≥64  16 2 ≤.5  ≤.25  ≤.25 ≤2  ≥16  ≤.25  ≤1  ≤16  ≤0.5  ≥320 
P26-79 
[202] 
urine UTI ≥32 128 ≥64 ≤4  ≥64  16  2  ≤0.5 ≤0.25 ≤0.25 ≤2  ≥16  ≤0.25  ≤0.5 32 ≤0.5 ≥320 
P26-81 
[206] 
urine UTI 16 32  ≥64 16  ≥64 16 2 ≤0.5 ≤0.25 ≤0.2 ≤2 ≥16  ≥4 ≤0.5 ≥512 ≤0.5 ≥320 
13 urine UTI ≤2 8 ≥64 ≤4 ≤1 ≤1 2 ≤1 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≤0.5 ≤16 ≤0.5 ≥320 
16 blood sepsis ≤2 8 ≥64 ≤4 ≤4 4 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≤0.5 ≤16 ≤0.5 ≥320 
27 urine UTI ≥32 8 ≥64 ≥64 ≤4 4 2 ≤0.5 2 ≤ 0.5 ≤2 ≤1 ≤0.25  1 ≥512 _ 80 
39 urine UTI ≤2 ≤4 ≤1  ≤4 ≤1  ≤1  ≤1  ≤0.5 ≤0.2 ≤0.25  ≤2  ≤1  ≤0.25  ≤0.5  32  ≤0.5  ≤20  
40 urine sepsis ≥32 ≥64 ≥64 ≤4  8 16 8 ≤ 0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≤0.25 1 64 ≤ 0.5 ≥320 
53 blood enteriti
s 









16 8 ≥64 ≤4 8 8 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 1 1 ≤16 ≤0.5 ≥320 
64 urine UTI 16 8 ≥64 ≤4 32 4 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 1 1 ≤16 ≤0.5 ≥320 





16 64 ≥64 16 8 2 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≥4 256 ≤0.5 ≥320 
84 w/swab W/I 16 8 ≥64 ≤4 32 8 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≤0.5 64 ≤0.5 ≥320 
99 urine UTI ≤2 16 ≥64 16 ≤4 16 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≥4 ≥128 ≤0.5 ≥320 
104 urine UTI ≥32 64 ≥64 ≤4 32 8 2 ≤1 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≤0.5 ≤16 ≤0.5 ≥320 
105 w/swab W/I 16 8 ≥64 ≤4 32 8 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≤0.5 64 ≤0.5 ≥320 
106 urine UTI 16 ≥64 ≥64 32 16 8 4 ≤0.5 ≤0.25 ≤0.25 4 ≥16 ≥16 ≤0.5 ≤16 ≤0.5 ≥320 
116 urine uroseps
is 
≥32 8 ≥64 32 4 8 ≤1  ≤1 ≤0.25 ≤2 ≤1 ≥8 ≥4 ≥512 ≤0.5 ≥320 
120 urine UTI 8 ≤4 ≥64 16 16 4 8 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≤2 ≥4 ≤16 ≤0.5 ≥320 
122 urine nephriti
s 
16 16 ≥64 ≤4 ≥64 4 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 2 4 64 ≤0.5 ≥320 
126 urine UTI 8 ≤4 2 16 ≤4 ≤1 ≤1 ≤0.5 ≤0.25 ≤0.25 ≤2 ≤1 ≤2 ≤0.5 ≤16 ≤0.5 ≥320 
127 blood sepsis 4 16 ≥64 ≤4 16 16 2 ≤0.5 ≤0.25 ≤1 ≤2 ≥16 ≤0.25 1 64 ≤0.5 ≥320 
132 w/swab W/I ≥32 ≥64 ≥64 8 ≥64 16 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 4 ≥128 ≤0.5 ≥320 
135 sputum tubercu
losis 




AMC- Amoxicillin-Clavulanate, TZP- Piperacillin Tazobactam, CXM-Cefuroxime, FOX-Cefoxitin CTX- Cefotaxime , CAZ- Ceftazidime, CFP- Cefepime, 
ETP- Ertapenem, IMP- Imipenem, MRP-Meropenem, AMK- Amikacin, GEN-Gentamicin, CIP-Ciprofloxacin, TET- Tetracycline, NIT- Nitrofurantoin, COL-
Colistin, SXT- Trimethoprim-sulfamethoxazole, W/swab-wound swab, W/I-wound infection, pneum-pneumoniae. B/L-bronchial lavage, bronch-bronchitis, UTI-







143 urine UTI 16 ≤4 16 2 16 ≤1 ≤1 ≤0.5 ≤0.25 ≤0.25 ≤2 ≤1 ≤0.25 1 32 ≤0.5 ≥320 
165 B/L bronch ≤2 8 ≥64 ≤4 32 8 2 ≤1 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≤0.5 ≤16 ≤0.5 ≥320 
172 w/swab WI ≥32 32 ≥64 ≤4 ≥64 4 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≤0.25 ≤1 ≤16 ≤0.5 ≥320 
193 sputum pneum 16 8 ≥64 ≤4 32 4 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≥16 ≥4 ≤0.5 64 ≤0.5 ≥320 
208 w/swab WI 16 ≤4 64 ≤4 32 8 2 ≤0.5 ≤0.25 ≤0.25 ≤2 ≤1 2 1 128 ≤0.5 ≥320 
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Abstract 
Metallo-β-lactamases (MBLs) are significant resistance factors in Gram-negative bacterial 
pathogens, which confer resistance to broad-spectrum β-lactams including carbapenems. A 
number of such enzymes have been described over the past decade. This study characterized 
isolates from a single, clinically significant MBL-producing P. aeruginosa clone from a tertiary 
hospital in Ghana whose MBL genes were identified in a class 1 integron. Isolates were 
identified by the Vitek‑2 (Biomerieux, France) automated systems and confirmed by MALDI-
TOF MS (Bruker Daltonic. Genomic DNA extraction was carried out using the NucliSens 
71 
 
easyMAG® (BioMérieux) kits.  Extracted DNA was subjected to whole genome sequencing on 
the Illumina MiSeq platform and analysed using CLC Genomics Workbench version 10.  The 
blaDIM-1 was 100% identical to the blaDIM-1 prototype gene, whereas blaIMP-34-like had two base 
pair changes in thymine (T) to cytosine (C) and guanine (G) to adenine (A) at 190 bp and 314 bp 
respectively compared to blaIMP-34 suggesting evolution of the gene perhaps through selection 
pressure. Both blaDIM-1 and blaIMP-34-like genes were linked to the type 1 integron structure. The 
four isolates belonged to the sequence type ST234. All the isolates carried other resistance genes 
most commonly aph(3')-IIb-like, qnrVC, fosA-like, sul1, dfrB5, catB7-like and arr-2 that 
mediated resistance to aminoglycoside, fluoroquinolone, fosfomycin, sulphonamide 
trimethoprim, phenicol and rifampin respectively. Detection of acquired MBL in clinical P. 
aeruginosa isolates is a clear cause for concern in Ghana as they eliminate the last resort 
carbapenems as therapeutic options for the management of multi-resistant Gam-negative 
pathogens.   
Keywords: Pseudomonas aeruginosa, IMP, DIM, carbapenemase, Ghana.  
  
Introduction  
Pseudomonas aeruginosa is a significant cause of nosocomial infections particularly in patients 
with compromised immunity. It is widespread in nature and readily acquires resistance to 
multiple classes of antibiotics. The emergence of  multi-drug resistant (MDR) P. aeruginosa in 
hospitals  and communities has led  to a loss  in the efficacy of most currently available 
antibiotics used for infection management (1). The mortality associated with MDR P. aeruginosa 
remains high.  Its  resistance to β-lactam antibiotics may be attributed to one or a combination of 
three mechanisms, i.e., porin alteration or loss, efflux and the expression of β-lactamases from all 
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four Ambler classes (2). The β-lactamase genes may be encoded chromosomally or borne by a 
diversity of mobile genetic elements (3, 4).  
 
The class A ESBLs including Temoneira (TEM-24), sulfhydryl variable (SHV-12), 
Cefotaximase-München (CTX-M-1, CTX-M-2, CTX-M-3), Vietnam extended-spectrum β-
lactamase (VEB)  as well as Klebsiella pneumoniae carbapenemases (KPC-2) have all been  
isolated from P. aeruginosa (5, 6). The metallo-β-lactamases, comprising of Verona integron-
encoded metallo-β-lactamases (VIM), impenemases (IMP), New Delhi metallo-β-lactamases 
(NDM) and Dutch impenemases (DIM) have also been isolated from P. aeruginosa in many 
parts of the world, as have been the cephamycinase (CMY), an  AmpC-β-lactamase,  and the 
oxicillinases (OXA) of the class D β-lactamases (7, 8). Various mobile genetic element (MGEs)  
that carry MBL genes have been identified, but the majority of them are found in the form of 
gene cassettes (blaIMP-like, blaVIM-like, blaDIM-1, and blaGIM-1) embedded into class 1 integron 
structures (9). Delineation of the clones and MGEs encoding the resistance genes in this 
pathogen is critical to contain their proliferation. We report on the complexity and diversity of 
MBL-mediated resistance from four isolates of P. aeruginosa from a teaching hospital in Ghana.  
Materials and Methods 
Ethical approval: Approval for this study was given by the Joint Committee on Human 
Research, Publications and Ethics, School of Medical Sciences, Kwame Nkrumah University of 
Technology, the Ethics Committee of Komfo Anokye Teaching Hospital (ref: 
CHRPE/AP/015/15), in Kumasi Ghana and the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal, South Africa with reference number BE 494/14. 
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Bacteria isolates: Multi-drug resistant P. aeruginosa were isolated from in-patients at Komfo 
Anokye Teaching Hospital in Ghana. The clinical isolates were identified by the Vitek‑2 
(Biomerieux, France) automated system and confirmed by MALDI-TOF MS (Bruker Daltonic 
Gmbh, Bremen, Germany). Four (4) out of thirty nine (39) isolates were selected for whole-
genome sequencing analysis based on their extensively drug-resistant (XDR) (isolate resistant to 
at least one agent in all but two or fewer antibiotic class) profiles (supplementary material 
MICs). Of the four samples from the in-patients, two were obtained from wound swabs in the 
surgical ward and one each from urine and pleural fluid in the Obstetrics and Gynaecology and 
Child Health Departments of the hospital respectively. Demographic characteristics and clinical 
diagnosis of each patient included in the study were obtained from the clinical records.  
Antimicrobial susceptibility testing: MICs of ampicillin, amoxicillin/clavulanate, 
piperacillin/tazobactam, cefuroxime cefotaxime, ceftazidime cefepime, gentamicin, amikacin, 
imipenem meropenem, ertapenem, and sulfamethoxazole/trimethoprim were ascertained by the 
Vitek‑2 (Biomerieux, France) automated system and confirmed by broth microdilution in 
accordance with European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines (10) 
 Whole Genome Sequencing: Genomic DNA extraction was carried out using the NucliSens 
easyMAG® (BioMérieux) kits according to the manufacturers’ instructions. The genomic DNA 
libraries were generated using the Nextera® kit (Illumina) followed by sequencing on an 
Illumina MiSeq platform at the Genomics Resource Center at UiT – The Arctic University of 
Norway.  
Bioinformatics analyses: Raw sequence reads were adaptor- and quality-trimmed using 
Trimmomatic (11) and subsequently assembled with Spades v.3.6.1 (12) using the careful flag. 
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For in-house analysis purposes, assemblies were annotated using prokka v.1.11(13) with further 
NCBI BLAST searches and manual annotation of mobile genetic elements and regions 
containing resistance genes as identified by ResFinder searches.  Assemblies deposited in 
GenBank were annotated using the PGAP pipeline provided by NCBI 
(http://www.ncbi.nlm.nih.gov/genome/annotation prok/), with additional manual curation of 
resistance gene and mobile genetic element annotations. Identification of resistance genes, 
particularly β-lactamases, was done with RAST 2.0 (14, 15). To identify the presence of plasmid 
DNA in isolates, raw reads were mapped to plasmid reference using bowtie2 v.2.2.6 (16) with 
“dovetail-no-unal”-flags enabled, and resulting bam files were passed through the BRIG 
coverage graph plugin to be used as input to BRIG (17) together with reference plasmids. 
Phylogenetic analyses were conducted by binning isolate assemblies by species and running 
them through parsnp v.1.2 (18) with “–c –x”-flags enabled. Phylogenetic trees were later edited 
with FigTree (http://tree.bio.ed.ac.uk/software/figtree/). Multi-locus sequence typing was done 
by feeding assemblies into the CGE MLST-server (v.1.8) (18).  To gain further insight into the 
genetic structures one of the isolates, P26-65, was subjected to long read sequencing by Oxford 
Nanopore. 
The raw read sequences and the assembled whole genome contigs have been deposited at the 
sequence read archive (SRA) and GenBank of NCBI, respectively, under bio-project number 
PRJNA411997. 
RESULTS 
Demographics, sample sources, wards, species and clones 
The four extensively drug resistant (XDR) P. aeruginosa had similar resistance profiles (Table 1) 
were selected for genetic analyses by whole genome sequencing (WGS). The isolates originated 
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from different patients and sources, and were collected at different time points and wards at the 
Komfo Anokye Teaching Hospital in Ghana (Table 1). Bioinformatics analyses (Table 2, Table 
S2) show all four isolates had the same sequence type of ST234. 
Genetic analyses of the blaDIM-1 and blaIMP-34-like containing regions 
The strain (P26-65) chromosome was circularized (Figure 3) and no plasmids were present. The 
resistance-encoding genes are marked in the figure together with the detected integron structures, 
i.e., integron 1 containing blaDIM-1 and integron 2 containing blaIMP-34-like gene. Further insights 
into the blaDIM-1- and blaIMP-34-like-encoding regions of the P26-85 chromosome were obtained 
by alignment with   the corresponding regions of P. aeruginosa strain (SMC4389) of ST654 
isolated in India by the use of Artemis Comparison Tool (ACT) (19). In Figure 4a (blaDIM-1) and 
Figure 4b (blaIMP-34-like) the putative integron structures (white arrows) are indicated. 
Moreover, the alignments revealed the presence of two genomic islands (green arrows) 
containing each of the integron structures. Both islands represent insertion of a DNA segment 
into the chromosome. 
The detected resistance encoding genes were identical in the four ST234 isolates, with the 
exception of qnrVC, which was additionally detected in P26-65 and P26-68; all four isolates 
were resistant to ciprofloxacin. Of specific interest are the blaDIM-1 and blaIMP-34-like genes 
detected in these four isolates.   Alignment of the blaDIM-1-positive contigs from each of the four 
samples showed that they had identical DNA sequences and sequence sizes (3093 bp); indicating 
that both resistance genes are flanked by repetitive elements that impairs the DNA assembly at 
this site. The same was shown for the blaIMP-34-like positive contigs (2656 bp). Comparisons of the 
detected blaDIM-1 was 100% identical to the blaDIM-1 prototype gene, whereas the blaIMP-34-like 
had two nucleotide changes in T190C and C314G respectively compared to blaIMP-34, leading to 
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one amino acid substitution in IMP-34-like β-lactamase. The base substitutions G:C→ A:T 
transitions or transversions are the most common spontaneous mutation type among bacteria  
(20-22). Also the variation or mismatch in GC-content is highly influenced  by natural selection 
or biased gene conversion (23), thus, suggesting, the blaIMP-34 gene may have evolved through 
selection pressure. BLAST analyses of the blaDIM-1-positive contig as well as the blaIMP-34-
positive contig did not reveal identical genetic structures deposited in NCBI, neither among the 
nucleotide collection, completed genomes nor among the completed plasmids. Moreover both 
blaDIM-1 and blaIMP-34 genes were not found to be widespread among bacterial sequences, 
deposited in NCBI (assessed November 2017). A linkage of both the blaDIM-1 and blaIMP-34-like 
genes to type1 integron structures, including the intI1 integrase encoding gene, was found by 
BLAST analyses of the assembled contigs. 
Phylogenetic analyses 
To investigate the global phylogeny and likely origins of these isolates, we added P. aeruginosa 
genome assembly datasets (n=417) downloaded from the PATRIC database 
(https://www.patricbrc.org/) as shown in Figure 1a. For each isolate included in the tree, country 
of origin, isolation source and MLST are given. The tree was coupled with the metadata using 
Phandango with the input files included (Figure S1 and Table S1). Arrows indicate the P. 
aeruginosa isolates from this study. In Figure 1b, the phylogenetic branch containing the blaDIM-
1 positive isolates were magnified. None of the closest neighbors encodes blaDIM-1 gene. They 
include isolates of ST111, ST381, ST252, ST654, and ST392 from different isolation sources 
and countries. Among the included genomes, one was positive for blaDIM-1 (GCA_001548335; 
blue) and four for blaIMP-34 (GCA_00291745; GCA_001547955; GCA_002201405; 
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GCA_02201455; red). These were closely related to the isolates from this study (indicated in 
orange) as evident in phylogenetic tree shown in Figure 2.  
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Table 1. Relevant patient data, source of specimens and antibiotic susceptibility of P. aeruginosa isolates (n=4) from teaching hospital 
in Ghana 
                                                                                           Extensively Drug resistant (XDR) isolates 
       Isolate                     Patient  Antibiotic Susceptibility profile  - MICs (mg/L) 
Code Collection 
Date  
WT Sex Age 
Yrs 
Source Diagnosis AMP AMC TZP CXM FOX CTX CAZ CFP IMP MEM AMK GEN CIP TET NIT COL SXT 
P26-65 
[97] 




≥512  ≤0.5  ≥320  
P26-67 
[130] 
  06/08/2015 Surg F 24 w/ 
swab 
SSI ≥32  ≥32  128 
  
≥64  ≥64  ≥64  ≥64  ≥64  ≥ 16   4 
  
≥32  ≥ 16  ≥4  ≥8 ≥512  ≤0.5  ≥320  
P26-68 
[140] 




≥32  ≥32  128 
  
≥64  ≥64  ≥64  ≥64  ≥64  ≥ 16  4 
  
≥32  ≥ 16  ≥4  ≥8 ≥512 ≤0.5  ≥320  
P26-69 
[142] 
 31/07/2015 CH F 0.5 P/ 
Fluid 
Peritonitis ≥32  ≥32  128 
  
≥64  ≥64  ≥64  ≥64  ≥64  ≥ 16  ≥ 16  ≥64  ≥ 16  ≥4  ≥8 ≥512  ≤0.5  ≥320  
                                                                    EUCAST  clinical breakpoints  
 
Resistant MICs breakpoint _ _ >16 _ NA _ >8 >8 >8 >8 >16 >4 >0.5 >2 _ >2 _ 
AMC- Amoxicillin-clavulanate, TZP- Piperacillin-Tazobactam, CXM-Cefuroxime, FOX-Cefoxitin CTX- Cefotaxime , CAZ- Ceftazidime, CFP- Cefepime, ETP- Ertapenem, 
IMP- Imipenem, MEM-Meropenem, AMK- Amikacin, GEN-Gentamicin, CIP-Ciprofloxacin, TET- Tetracycline, NIT- Nitrofurantoin, COL-Colistin, SXT- trimethoprim-
sulfamethoxazole, CH- Child Health, O&G-Obstetrics and Gynecology, Med-Medicine, Surg- Surgery, WT-Ward type, SPM-Specimen, SSI-Surgical site infection, P/fluid-pleural 
























                                                                        Resistance Genes 
 β-lactams  Aminoglycoside
s 
Quinolones Fosfomycin Sulphonamide Trimethoprim Phenicols Rifampin 
 
              
P26-65 
[97] 










qnrVC fosA-like sul1 dfrB5 catB7-like arr-2 
P26-67 
[130] 










 fosA-like sul1 dfrB5 catB7-like arr-2 
P26-68 
[140] 










qnrVC fosA-like sul1 dfrB5 catB7-like arr-2 
P26-69 
[142] 






















Figure 1a. Phylogenetic tree of P. aeruginosa genome assembly datasets (n=417) downloaded 
from the PATRIC database (https://www.patricbrc.org/). Clustering of the strains into clades was 
mainly by country of origin, isolation source and MLST. Arrows indicate the P. aeruginosa isolates 













Figure 1b. Phylogenomic tree containing encompassing blaDIM-1 and blaDIM-1 positive P. 
aeruginosa isolates. Clustering of the strains into clades were isolates of ST111, ST381, ST252, 
ST654, and ST392 from different isolation sources (clinical and environment) and countries 
(Belgium, Turkey, France, Colombia, Greece, India, Ghana and USA). The genomic phylogeny 









Figure 2. Evolutionary relatedness of P. aeruginosa strains from Ghana. Phylogenomic tree from 
metadata drawn by the use of Phandango. Among the genomes included, one was positive for blaDIM-1 
(GCA_001548335)[blue] and four for blaIMP-34 (GCA_00291745; GCA_001547955; 
GCA_002201405; GCA_02201455) [red], which indicates that, they were closely related to the 










Figure 3. Representation of chromosome structure of P. aeruginosa strain (P26-65) by oxford 
Nanopore sequence. The resistance encoding genes are marked together with the detected integron 
structures, Integron 1 and Integron 2 containing blaDIM-1 and blaIMP-34-like respectively. A third 










Figure 4a. Alignment of the blaDIM-1 encoding regions of P. aeruginosa (P26-85) chromosome 
with the corresponding regions of SMC4389 (GCA_001482875) of ST654 isolate using 
Artemis Comparison Tool to graphically show the relationship between the two integron 
structures. The alignment revealed the presence of two genomic islands containing each of the 
integron structures represented in green arrows with the putative integron structures indicated in 











Figure 4b. Alignment of blaIMP-34-like encoding regions of P. aeruginosa (P26-85) chromosome 
with the corresponding regions of SMC4389 (GCA_001482875) of ST654 using Artemis 
Comparison Tool to graphically show the relationship between the two integron structures. The 
putative integron structures (white arrows) with the two genomic islands containing each of the 
integron structures (green arrows) on top of the figure. Both islands represent insertion of the DNA 






















Metallo-β-lactamase (MBL)-producing P. aeruginosa is among the ESKAPE Gram-negative 
pathogens that have evolved to exhibit high levels of extensive drug resistance including 
carbapenem resistance. MBL production is a major mechanism by which P. aeruginosa 
acquires resistance to carbapenems. Despite the emergence of MBL-producing P. 
aeruginosa, no surveillance data and genomic characterization have so far been reported from 
Ghana. This study represents the first detailed report on molecular characterization of MBL-
producing P. aeruginosa using whole genome sequencing. We identified four P. aeruginosa 
isolates resistant to all antibiotics tested except colistin. The four isolates harboured blaDIM-1 
and blaIMP-34-like gene and have the same sequence type (ST234). Both blaDIM-1 and blaIMP-34-
like positive contigs showed that the four isolates have identical DNA sequences representing 
one clone.  Analyses of the blaDIM-1 and blaIMP-34 positive contigs indicated a linkage of both 
the blaDIM-1 and blaIMP-34-like to type 1 integron structure with the intI1 integrase encoding 
gene. 
 
The four XDR P. aeruginosa isolates were resistant to all tested β-lactams including 
carbapenems and the combination of β-lactam/lactamase inhibitors such as amoxicillin-
clavulanate and piperacillin-tazobactam were also not active against the isolates. The 
resistance to carbapenems is particularly challenging to clinical practice posing a serious 
threat to antibiotic therapy as these agents are regarded as most effective β-lactam antibiotics 
against MDR Gram-negative bacteria including P. aeruginosa in Ghana (24). Thus, stringent 
antibiotic stewardship programmes should be enforced to combat the spread of MBL-




The blaDIM-1 and blaIMP-34-like genes were identified in the XDR isolates belonging to ST234. 
Reports from several hospitals in Moscow have indicated the prevalence of MBL-producing 
P. aeruginosa ST234, but these were associated with VIM-2 producers (25). Genomic data 
analysis found one closely related isolate from India, i.e., P. aeruginosa strain SMC4389 
(GCA_001482875) belonging to ST654. However, this isolate did not contain the blaDIM-1 
and blaIMP-34-like genetic structure. This finding intimates that the genetic elements 
containing these resistance genes had been acquired, but from an unknown source, 
confirming reports from studies that, many African countries do not undertake 
epidemiological surveillance of carbapenems resistance and carbapenemase genes (26, 27). 
Further phylogenic investigation on our isolates from 417genome assembly datasets from 
different isolation sources, countries and MLST showed that none of the closest neighbors 
encodes blaDIM-1 genes. This suggests that these carbapenem-resistant P. aeruginosa isolates 
emerged independently, possibly through selection pressure, and are disseminating locally 
through clonal expansion, probably due to poor adherence to infection control protocols. Our 
study indicated that there were no plasmids present in the circularized chromosome, implying 
that the IMP and DIM carbapenemases were chromosomal and corroborated the clonal 
dissemination of the P. aeruginosa strains isolated from different patients, sources and wards 
in the hospital.  
 
We found a linkage of blaDIM-1 and blaIMP-34-like genes to type1 integron structures and intI1 
integrase encoding gene by BLAST analysis. The blaDIM-1 in the form of gene cassette 
inserted at intI1 is similar to other acquired MBLs in Gram-negative bacteria commonly 
located in class 1 integrons (28, 29). Studies have reported blaIMP-types as one of the most 
common families of acquired MBLs in Enterobacteriaceae including P. aeruginosa (29, 30). 
A number of  MBL types in carbapenem-resistant P. aeruginosa, including IMP-like and 
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DIM-like types, have been reported from many parts of the world (8, 31). Class 1 integrons, 
which carry MBL genes and genes encoding resistance determinants of other antibiotics such as 
aminoglycosides and trimethoprim, mobilise and transfer extensive drug resistance within and 
between species (32, 33). Reports from other studies have indicated that class 1 integrons are often 
chromosomally located and associated with genomic islands of pathogenic bacteria such as P. 
aeruginosa evident in this study (34, 35). This presents a major challenge to both clinical 
treatment and infection control management given the limited healthcare logistics in Ghana. 
Therefore, studies on dissemination of MBLs among other Gram-negative isolates, 
particularly the Enterobacteriaceae is crucial for the development of strategies to contain the 
spread of these resistance genes. This study should be extended to hospitals in the other 
regions of Ghana. 
Conclusion 
We report herein the first carbapenem-resistant and carbapenemase producing P. aeruginosa 
clonal outbreak in a tertiary hospital in Ghana. Chromosomally mediated blaDIM-1 and blaIMP-
34-like carbapenemases are circulating in P. aeruginosa ST234 clones in Komfo Teaching 
Hospital, Ghana. Stricter infection control, contact precautions, antibiotic stewardship and 
surveillance are necessary to identify and contain the spread of this XDR pathogen. 
Acknowledgements 
We are grateful to Komfo Anokye Teaching Hospital staff, especially the technical staff in 
the Microbiology laboratory for their support during sample collection and preliminary 
identification as well as the physicians and nursing staff in various wards for their 
cooperation. We thank the staff of National Health Laboratory Services (NHLS), Albert 
Luthuli Hospital in South Africa for further bacteria identification and the antibiotics 
susceptibility profile testing. We also thank Bettina Aasnæs and Ellen Josefsen of University 




This study was supported by the National Research Foundation Incentive Funding for Rated 
Researchers (Grant No.: 85595) and a PhD Scholarship awarded to N Agyepong by the 
College of Health Sciences, University of KwaZulu-Natal. Any opinion, finding and 
conclusion or recommendation expressed in this material is that of the author(s) and the NRF 
does not accept any liability in this regard. 
 
References 
1. Ullah W, Qasim M, Rahman H, Bari F, Khan S, Rehman ZU, Khan Z, Dworeck T, 
Muhammad N. 2016. Multi drug resistant Pseudomonas aeruginosa: Pathogen burden 
and associated antibiogram in a tertiary care hospital of Pakistan. Microb Pathog 
97:209-212. 
2. Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. 
Antimicrob Agents Chemother 54:969-976. 
3. Zhao W-H, Hu Z-Q. 2013. Epidemiology and genetics of CTX-M extended-spectrum 
β-lactamases in Gram-negative bacteria. Crit Rev Microbiol 39:79-101. 
4. El Salabi A, Walsh TR, Chouchani C. 2013. Extended spectrum β-lactamases, 
carbapenemases and mobile genetic elements responsible for antibiotics resistance in 
Gram-negative bacteria. Crit Rev Microbiol 39:113-122. 
5. Chen Z, Niu H, Chen G, Li M, Li M, Zhou Y. 2015. Prevalence of ESBLs-producing 
Pseudomonas aeruginosa isolates from different wards in a Chinese teaching hospital. 
Int J Clin Exp Med 8:19400. 
6. Poirel L, Nordmann P, Lagrutta E, Cleary T, Munoz-Price LS. 2010. Emergence of 
KPC-producing Pseudomonas aeruginosa in the United States. Antimicrob Agents 
Chemother 54:3072-3072. 
7. Zafer MM, Al-Agamy MH, El-Mahallawy HA, Amin MA, Ashour MSE-D. 2014. 
Antimicrobial resistance pattern and their β-lactamase encoding genes among 
Pseudomonas aeruginosa strains isolated from cancer patients. BioMed Res Int 
2014:23-32. 
8. Hong DJ, Bae IK, Jang I-H, Jeong SH, Kang H-K, Lee K. 2015. Epidemiology and 
characteristics of metallo-β-lactamase-producing Pseudomonas aeruginosa. Infect 
Chemother 47:81-97. 
9. Poirel L, Pitout JD, Nordmann P. 2007. Carbapenemases: molecular diversity and 
clinical consequences. Future Microbiol 2:501-512. 
10. European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint 
tables 446 for interpretation of MICs and zone diameters, version 7.0. Växjö: 
EUCAST (valid from 2017-01-01). p 1-93. 
11. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina 
sequence data. Bioinformatics 30:2114-2120. 
12. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, 
Nikolenko SI, Pham S, Prjibelski AD. 2012. SPAdes: a new genome assembly 
algorithm and its applications to single-cell sequencing. J Comput Biol 19:455-477. 
89 
 
13. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 
30:2068-2069. 
14. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes 
S, Glass EM, Kubal M. 2008. The RAST Server: rapid annotations using subsystems 
technology. BMC Genomics 9:75-90. 
15. Brettin T, Davis JJ, Disz T, Edwards RA, Gerdes S, Olsen GJ, Olson R, Overbeek R, 
Parrello B, Pusch GD. 2015. RASTtk: a modular and extensible implementation of 
the RAST algorithm for building custom annotation pipelines and annotating batches 
of genomes. Sci Rep 5:8365-8371. 
16. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat 
Methods 9:357-359. 
17. Alikhan N-F, Petty NK, Zakour NLB, Beatson SA. 2011. BLAST Ring Image 
Generator (BRIG): simple prokaryote genome comparisons. BMC Genomics 12:402-
412. 
18. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, 
Pontén TS, Ussery DW, Aarestrup FM. 2012. Multilocus sequence typing of total 
genome sequenced bacteria. J Clin Microbiol 50:1355-1361. 
19. Carver TJ, Rutherford KM, Berriman M, Rajandream M-A, Barrell BG, Parkhill J. 
2005. ACT: the Artemis comparison tool. Bioinformatics 21:3422-3423. 
20.     Sung W, Ackerman MS, Gout J-F, Miller SF, Williams E, Foster PL, Lynch M. 2015. 
Asymmetric context-dependent mutation patterns revealed through mutation–
accumulation experiments. Molecular Biology and Evolution 32:1672-1683. 
21. Long H, Kucukyildirim S, Sung W, Williams E, Lee H, Ackerman M, Doak TG, 
Tang H, Lynch M. 2015. Background mutational features of the radiation-resistant 
bacterium Deinococcus radiodurans. Molecular Biology and Evolution 32:2383-2392. 
22. Lee H, Popodi E, Tang H, Foster PL. 2012. Rate and molecular spectrum of 
spontaneous mutations in the bacterium Escherichia coli as determined by whole-
genome sequencing. Proceedings of the National Academy of Sciences 109:2774-
2783. 
23. Hildebrand F, Meyer A, Eyre-Walker A. 2010. Evidence of selection upon genomic 
GC-content in bacteria. PLoS genetics 6:1-9. 
24. Agyepong N, Govinden U, Owusu-Ofori A, Essack SY. 2018. Multidrug-resistant 
gram-negative bacterial infections in a teaching hospital in Ghana. Antimicrob Resist 
Infect Control 7:37-45. 
25.      Edelstein MV, Skleenova EN, Shevchenko OV, D'souza JW, Tapalski DV, Azizov IS, 
Sukhorukova MV, Pavlukov RA, Kozlov RS, Toleman MA. 2013. Spread of 
extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, 
Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet 
Infect Dis 13:867-876. 
26.       Leski TA, Bangura U, Jimmy DH, Ansumana R, Lizewski SE, Li RW, Stenger DA, 
Taitt CR, Vora GJ. 2013. Identification of blaOXA-51-like, blaOXA-58, blaDIM-1 
and blaVIM Carbapenemase Genes in Hospital Enterobacteriaceae Isolates from 
Sierra Leone. J Clin Microbiol 51:2435-2443. 
27.       Nordmann P, Dortet L, Poirel L. 2012. Carbapenem resistance in Enterobacteriaceae: 
here is the storm! Trends Mol Med 18:263-272. 
28. Stokes H, Martinez E, Chowdhury PR, Djordjevic S. 2012. Class 1 integron-
associated spread of resistance regions in Pseudomonas aeruginosa: plasmid or 
chromosomal platforms? J Antimicrob Chemother 67:1799-1800. 
29. Poirel L, Rodríguez-Martínez J-M, Al Naiemi N, Debets-Ossenkopp YJ, Nordmann 
P. 2010. Characterization of DIM-1, an integron-encoded metallo-β-lactamase from a 
90 
 
Pseudomonas stutzeri clinical isolate in the Netherlands. Antimicrob Agents 
Chemother 54:2420-2424. 
30. Nordmann P, Poirel L. 2014. The difficult‑to‑control spread of carbapenemase 
producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20:821-830. 
31. Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N. 2014. Dominance 
of international ‘high-risk clones’ among metallo-β-lactamase-producing 
Pseudomonas aeruginosa in the UK. J Antimicrob Chemother 70:103-110. 
32. Cornaglia G, Giamarellou H, Rossolini GM. 2011. Metallo-β-lactamases: a last 
frontier for β-lactams? Lancet Infect Dis 11:381-393. 
33. Wright LL, Turton JF, Hopkins KL, Livermore DM, Woodford N. 2015. Genetic 
environment of metallo-β-lactamase genes in Pseudomonas aeruginosa isolates from 
the UK. J Antimicrob Chemother 70:3250-3258. 
34.      Papagiannitsis CC, Medvecky M, Chudejova K, Skalova A, Rotova V, Spanelova P, 
Jakubu V, Zemlickova H, Hrabak J. 2017. Molecular characterization of 
carbapenemase-producing Pseudomonas aeruginosa of Czech origin: evidence for 
clonal spread of extensively resistant ST357 expressing IMP-7 metallo-β-lactamase. 
Antimicrobial Agents and Chemotherapy 61:1811-1817. 
35.      Martinez E, Marquez C, Ingold A, Merlino J, Djordjevic SP, Stokes H, Chowdhury 
PR. 2012. Diverse mobilized class 1 integrons are common in the chromosome of 























Supplementary Material: MICs 
Isolate 
code 
specimen  Susceptibility profile  - MICs (mg/L) 
  
AMP AMC TZP CXM FO
X 
CTX CAZ CFP ETP IMP MEM AMK GEN CIP  TET NIT COL SXT 
P26-65 
 [97] 
urine  ≥32   ≥32  ≥128 ≥64 ≥64 ≥64  ≥64 ≥64  - ≥16 ≥1 ≥64 ≥16  ≥4  ≥8  ≥512  ≤0.5  ≥320  
P26-67 
[130] 
W/swab ≥32 ≥32  128 ≥64 ≥64 ≥64 ≥64  ≥64  - ≥ 16  4  ≥32  ≥ 16 ≥4  ≥8 ≥512  ≤0.5 ≥320  
P26-68 
[140] 
W/swab ≥32  ≥32  128 ≥64  ≥64 ≥64 ≥64 ≥64 - ≥ 16 4 ≥32  ≥ 16 ≥4 ≥8 ≥512 ≤0.5  ≥320 
P26-69 
[142] 
P/fluid ≥32 ≥32  128 ≥64 ≥64  ≥64  ≥64 ≥64 - ≥ 16  ≥ 16 ≥64  ≥ 16 ≥4  ≥8 ≥512  ≤0.5  ≥320  
P26-64 
[85] 
W/swab ≥32 ≥32 32 ≥64  ≥64  8  ≤1  8  - ≤1 ≤0.25 ≤2  4 ≥4 ≥8 ≥512 ≤0.5 160 
2 W/swab ≥32  ≥32   8 ≥64 ≥64 8 ≤1  ≤1  -  2   1 ≤2  ≤1 ≤0.25  8  ≥512  ≤0.5 80  
14 sputum ≥32 ≥32   8 ≥64  ≥64 32  2 2   2  ≤0.25 ≤2  ≤1  ≤0.25 8  ≥512  ≤0.5  80  
22 urine ≥32  ≥32  64 ≥64  ≥64 ≥64  4  2  - 1 1  ≤2 ≥16 ≥4 ≥8  ≥512 ≤0.5 ≥320  
25 W/swab ≥32  ≥32  8 ≥64 ≥64  32 4  ≤1  - 2  ≤0.25 ≤2  ≤1 ≤0.25 8  ≥512 ≤0.5  160 
28 E/swab ≥32  ≥32   8 ≥64 ≥64 32 4 2  - 2 ≤0.5 ≤2 ≤1  ≤0.25 ≥8 ≥512  - 80 
32 urine ≥32 ≥32 8 ≥64 ≥64  8  ≤1 ≤1 - 2 1  ≤2  ≤1  ≤0.25 ≥8  ≥512  ≤0.5  80  
43 W/swab ≥32 ≥32 8  ≥64  ≥64  16  ≤1  ≤1  - 2  0.5  ≤2  ≤1  ≤0.25  ≥8 ≥512 ≤0.5 40  
44 W/swab ≥32  ≥32  8  ≥64  ≥64  8  ≤1  ≤1  - 1  ≤0.5 ≤2  ≤2  ≤0.25 ≥8  ≥512  ≤0.5 80  
49 W/swab ≥32  ≥32  8 ≥64  ≥64  16 2  ≤1  - 2  ≤0.25 ≤2  ≤1  ≤0.25  ≥8 ≥512 ≤0.5  160  
51 W/swab ≥32  16 32  ≥64 ≥64 ≥64 4  4 - 0.5 1 ≤2 ≥16 ≥4 ≥8 ≥512 ≤0.5  ≥320  
54 sputum ≥32  ≥32  8  ≥64 ≥64 ≥64 4  2  - 2  ≤0.25  4 ≤1  ≤0.25 ≥8 256 ≤0.5  80 
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58 sputum ≥32 ≥32 8  ≥64 ≥64 32 2  4 - 1 ≤0.25 4  4  ≤0.5  ≥8  ≥51 ≤0.5 ≥320  
59 urine ≥32    ≥32 ≤4 ≥64 ≥64 8  ≤1  ≤1 - 2 0.5  ≤2  ≤1  ≤0.25 ≥8  ≥512 ≤0.5 ≥320 
62 N/swab ≥32  ≥32    8 ≥64 ≥64 8 ≤1 ≤1  - 2 ≤0.25  ≤2 ≤1  ≤0.25  ≥8 ≥512 ≤0.5  80 
65 G/lavage ≥32  ≥32   8 ≥64  ≥64 8  ≤1 ≤1  - 1 ≤0.25 ≤2  ≤1  ≤.25  ≥8 ≥512 ≤0.5 80 
67 urine ≥32  ≥32 8 ≥64 ≥64   32 4  2 - 1 ≤0.25 ≤2  ≤1 ≤0.25 ≥8 ≥512 ≤0.5 ≥320 
85 W/swab ≥32  ≥32  32 ≥64  ≥64  8  ≤1 8  - ≤1  ≤0.25 ≤2  4  ≥4 ≥8 ≥512 ≤0.5 160 
86 blood 16  4  ≤4 16  ≥32  8  4  2  - ≤0.25 ≤0.25 ≤2 ≤1 ≤0.25 ≤0.5 128  ≤0.5 ≤20 
87 W/swab ≥32 ≥32  8 ≥64  ≥64  32 ≤4  ≤2 - ≤1 ≤0.25 ≤2 ≤1  ≤0.25 8  ≥512 ≤0.5 160 
88 W/swab ≥32 ≥32 8 ≥64  ≥64  ≥16 ≤1 2  - 2 ≤0.25 ≤2 ≤1 ≤0.25 ≥8 ≥512 ≤0.5 80 
91 urine  ≥32   ≥32 8 ≥64 ≥64   32 4  2  2  ≤0.25 ≤2  ≤1  ≤0.25 ≥8  ≥512 ≤0.5 80 
119 urine ≥32  ≥32  8 ≥64 ≥64 16 2  ≤1   2  ≤0.25  ≤2  ≤1  ≤0.25  ≥8  ≥512 ≤0.5  80  
121 W/swab ≥32  ≥32 8 ≥64 ≥64  32  4 2  - 2 ≤0.25 ≤2  2  ≤0.25 ≥8  ≥512  ≤0.5  160  
123 W/swab ≥32  ≥32 8 ≥6 ≥6 32 4 2  2  ≤0.25 ≤2  ≤1 ≤0.5 ≥8  ≥512 ≤0.5 160 
124 sputum ≥32 ≥32 8 ≥64 ≥64 32 4  2  1 ≤0.5 ≤2 2 0.5 ≥8 ≥512 ≤0.5 ≥320 
134 urine ≥32  ≥32  8 ≥64 ≥64       32  4  2 - 2 ≤0.5 ≤2  ≤1 ≤0.25 ≥8 ≥512 ≤0.5 80 
145 urine ≥32  ≥32 8 ≥64 ≥64  16 4  2  - 2  ≤0.25  ≤2  ≤1  ≤0.25  ≥8  ≥512  ≤0.5 ≥320  
`146 urine ≥32  ≥32 8 ≥64  ≥64 16 4 2 - 1  ≤0.25  ≤2 ≤1  ≤0.25  ≥8  ≥512 ≤0.5  160  
150 urine ≥32  ≥32  8 ≥64 ≥64 32  4  2 - 2  ≤0.25  ≤2  ≤1  0.5  ≥8  ≥512 ≤0.5 160  




AMP-Ampicillin, AMC- Amoxicillin-clavulanate, TZP- Piperacillin-Tazobactam, CXM-Cefuroxime, FOX-Cefoxitin CTX- Cefotaxime , CAZ- Ceftazidime, CFP- Cefepime, ETP- Ertapenem, 
IMP- Imipenem, MEM-Meropenem, AMK- Amikacin, GEN-Gentamicin, CIP-Ciprofloxacin, TET- Tetracycline, NIT- Nitrofurantoin, COL-Colistin, SXT- trimethoprim-sulfamethoxazole 
P/fluid-pleural fluid, w/swab-wound swab, P/swab-pleural swab, G/lavage-gastric lavage, N/swab-nasal swab.
161 W/swab ≥32  ≥32 8 ≥64 ≥64 1 4 ≤1 - 2 ≤0.25 ≤2 ≤1 ≤0.25 ≥8 ≥512 ≤0.5 80 
176 sputum ≥32  ≥32 ≤4 ≥64 ≥64 8 ≤1  ≤1  1  ≤0.25 ≤2 ≤1 ≤0.25  ≥8 ≥512 ≤0.5 ≥320 





                Conclusions, Recommendation and Significance 
6.1 Conclusion 
Antibiotic resistance among Gram-negative ESKAPE pathogens poses a major challenge in 
Komfo Anokye Teaching Hospital and associated with adverse outcomes in treatment of 
infections in Ghana.  
Key findings were as follows: 
• The most predominant bacteria were P. aeruginosa and K. pneumoniae accounting for 
40.2% and 39.2% respectively, followed by E. cloacae, 12.4% and A. baumanii, 8.2% 
as the least of the Gram-negative ESKAPE pathogens. 
• The bacteria were multidrug and extensively-drug resistant, however meropenem was 
noted as the most effective β-lactam antibiotic in Ghana. 
• The presence of β-lactamase genes in diverse combination with non-β-lactamase 
resistance genes was found among the pathogens. 
• The ten MDR K. pneumoniae isolates evidenced multiple resistance genes conferring 
resistance to multiple antibiotic classes with β-lactams (blaCTX-M-15, blaSHV-11, blaTEM-
1B), aminoglycosides (aac(3)-IIa-like, aph(3')-Ia, aac(6')Ib-cr) and fluoroquinolones 
(oqxA-like, oqxB-like, qnrB10-like, qnrB2) being the most common.  Other resistance 
genes such as sul2, fosA and dfrA14 encoding resistance for sulphonamide, fosfomycin 
and trimethoprim respectively were also identified. 




• Multiple and diverse mutations were detected in quinolone resistance-determining 
regions of gyrA, gyrB and parC genes among K. pneumoniae with S83F/Y and D87A 
of gyrA and S80I in parC as most common mutations observed among the 
fluoroquinolone-resistant isolates.  
o No mutation was detected in gyrB among fluoroquinolone-resistant isolates 
with a ciprofloxacin MIC ≥4mg/L. 
• The four XDR P. aeruginosa isolates belonged to  same sequence type ST234 had: 
o The identical resistance gene profile consisting of β-lactamases (blaDIM-1 
blaIMP-34-like, blaOXA-10-like, blaOXA-129, blaOXA-50-like, blaPAO-like), 
aminoglycosides (aadA1-like, aph(3')-IIb-like, aacA4), fosfomycins (fosA-
like), sulphonamides (sul1), trimethoprim (dfrB5), phenicols (catB7-like) and 
rafampins (arr-2) 
o The blaDIM-1 and blaIMP-34-like were linked to type 1 integron structures  
• Although not reported in the manuscripts, we also undertook WGS of two each of E. 
cloacae and A. baumanii (Supplementary data).  
o WGS revealed β-lactamases (carbapenemases) encoding genes blaADC-25 and 
blaOXA-91 and aminoglycosides resistance gene (aadB) co-expressed with the 
tetracycline resistance gene tetB was found in A.  baumannii.  
o β-lactamases (blaTEM-1B, blaSHV-11, blaOXA-1 and blaCTX-M-15), resistance genes to 
aminoglycosides (aac(6’)Ib-cr, aac(3)-IIa, strB and strA) were expressed in E. 
cloacae with quinolones/fluoroquinolones efflux pumps (oqxA, oqxB and 
qnrB) most predominant E. cloacae (n=1) isolate. 
6.2 Limitations 
• The use of Illumina sequencing precluded the definitive association of antibiotic 
resistance genes with plasmids and detailed plasmid analysis. 
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• Financial constraints precluded the WGS of all isolates 
• Isolates for whole genome sequencing were not randomly selected, presenting a 
potential bias.  Notwithstanding, random sampling may have precluded stratified 
sampling precision and equal representation of isolates collected from each group of 
Gram-negative ESKAPE pathogens. 
6.3 Recommendations 
•  High prevalence of multidrug resistance was observed among Gram-negative 
ESKAPE pathogens in KATH. Studies should be extended to other health care 
settings over a longer period of time with larger sample size for representivity. 
• Antibiotic stewardship programs should be strictly enforced to maintain the efficacy 
of the carbapenems (meropenem). 
• Regular education on antibiotic resistance awareness, contact precaution and infection 
control measures among health care professionals should be encouraged to combat the 
spread of resistant bacteria. 
• Comprehensive molecular characterization to delineate antibiotic resistance 
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Supplementary Data   
Table 1:  Phenotypic Profile of WGS A. baumanii and E. cloacae Isolates 
Code  Susceptibility profile  - MICs (ug/mL) 
Species AMC TZP CXM FOX CTX CAZ CFP ETP IMP MEM AMK GEN CIP  TET NIT CO
L 
SXT 
151 A. baumannii ≥32 ≥128 ≥64 ≥64  ≥64  ≥64 ≥64 - 0.5  1 ≤2  ≥16  ≥4  4  ≥512 ≤0.5  ≥320  
198 A. baumannii 8 16 ≥64 ≥64 32 16 8 - ≤0.25  ≤0.25 ≤2 ≤1 ≤0.25 ≤.5 ≥512 ≤0.5 ≤20  
170 E. cloacae 
≥32  64 
 
≥64  ≥64  ≥64  ≥64  ≤1  ≤0.5 ≤0.25  ≤0.25  ≤2  ≤1  ≤0.25  1 
  
128  ≤0.5  ≤20 
194 E. cloacae 
≥32  ≥128  ≥64  ≥64  ≥64  ≥64  ≥64  ≤1  ≤0.25  ≤0.25  ≤2 
  




256  ≤0.5  ≥320  
Abbreviations: AMC- Amoxicillin-clavulanate, TZP- Piperacillin Tazobactam, CXM-Cefuroxime, FOX-Cefoxitin CTX- Cefotaxime , CAZ- Ceftazidime, CFP- Cefepime, 
ETP- Ertapenem, IMP- Imipenem, MRP-Meropenem, AMK- Amikacin, GEN-Gentamicin, CIP-Ciprofloxacin, TET- Tetracycline, NIT- Nitrofurantoin, COL-Colistin, SXT- 
Trimethoprim-sulfamethoxazole, Obs& Gyn. -Obstetrics and Gynaecology,  
 
Table 2:  Patient Demographic and Clinical Records 
Isolate  
P-number 
Code Species Collection date                                                      Patient 
Specimen Age (yr) sex diagnosis ward type 
P26-70 151 A. baumannii  09/09/2015 Urine 5 F UTI ICU 
P26-77 198 A. baumannii  09/03/2015 Urethral swab 30 F UTI ICU 
P26-73 170 E. cloacae  11/06/2015 Aspirate 3 M Scalp abscess OPD 







Table 3:  WGS and Bioinformatics Analyses with Resistance Genes 
Isolate  
P-number 























sul2 tet(39)  





sul2 tet(39)  
P26-73 5096234 175x 64   fosA-like      











sul2   
 
 








                                                                           PlasmidFinder 
                   Plasmids   IncHI1 IncF pMLST summary 
P26-70 A. baumannii ST-1418       
P26-77 A. baumannii ST-1418       
P26-73 E. cloacae 
Unknown 
ST NA      
P26-76 E. cloacae ST-456 IncQ1,ColRNAI      
 
